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ABSTRACT  
Annexin A2 (ANXA2), a calcium-dependent membrane binding protein shown to promote 
membrane domain formation, is implicated in many cellular processes. In order to determine if 
ANXA2 promotes domain formation by self-associating with the N-terminal domain of adjacent 
ANXA2 proteins upon binding anionic phospholipids, Forster Resonance Energy Transfer (FRET) 
assays were performed using ANXA2 proteins fluorescently labeled at the singular, exposed N-
terminal cysteine residue. No FRET transfer was observed, suggesting that under these 
experimental conditions the N-terminal domains do not interact. 
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CHAPTER 1—INTRODUCTION 
Annexins are a family of structurally conserved peripheral membrane proteins which bind anionic 
phospholipids in a calcium-dependent manner. These proteins have a structurally conserved C-
terminal core domain and an N-terminal domain which is unique to each annexin protein (Ayala-
Sanmartin, Zibouche, Illien, Vincent, & Gallay, 2008). Annexins are implicated in human health 
and disease and affect a diverse array of cellular processes; particularly related to membrane 
functions. Annexin A2 (ANXA2) is regarded as the annexin protein most extensively investigated 
regarding human health and disease” (Hajjar, 2015). 
The ANXA2 gene is comprised of 13 exons on chromosome 15q21 (Hedhli et al., 2012). Over 
time, ANXA2 has been referred to as calpactin I heavy chain (CAL1H), annexin II, chromobindin 
8, lipocortin II, and placental anticoagulation protein IV (Saxena, Lai, Chao, Jeng, & Lai, 2012). 
ANXA2 is present in endothelial cells, monocytes, macrophages and many cancer cells 
(Bharadwaj, Bydoun, Holloway, & Waisman, 2013). In cancer cells, ANXA2 and its binding 
partners, such as S100A10, have been shown to promote metastasis by remodeling actin and 
regulating the cytoskeleton (Lokman, Ween, Oehler, & Ricciardelli, 2011). As a mediator of the 
plasminogen activator system, ANXA2 plays a role in regulating thrombolysis, fibrinolysis, and 
wound healing (Lokman et al., 2011). Additionally, ANXA2 mediates endocytosis, exocytosis, 
lipid raft formation, and lipid and calcium signaling.  
The physiological importance of the calcium-dependent phospholipid and membrane binding of 
ANXA2 in these cellular processes is currently being elucidated (Gerke & Moss, 2002). Modifying 
the calcium concentration, pH level, or the anionic phospholipid composition has been shown to 
alter ANXA2 interactions with anionic phospholipids both in vitro and in vivo. Alterations in 
ANXA2 organization at the plasma membrane under differing reaction conditions indicates that 
under specific conditions ANXA2 may undergo a conformational or physiological change; which 
could explain its diverse role within the human body.  
The N-terminal domain is likely the region of ANXA2 most effected by a conformational or 
physiological change because it has been shown to regulate the function of ANXA2 by altering 
calcium affinities at protein-interaction sites in the core domain (Gerke, Creutz, & Moss, 2005). 
Many researchers have characterized the core domain of different annexins, but there are still a lot 
of questions regarding the role of the N-terminal domain of annexins in cellular processes; 
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particularly in the calcium-dependent membrane bridging of annexins (Ayala-Sanmartin et al., 
2008). 
ANXA2 has a single exposed cysteine residue on its N-terminal residue which can be fluorescently 
labeled and studied using techniques such as fluorescence resonance energy transfer (FRET) or 
fluorescence lifetime imaging microscopy (FLIM). FLIM can more accurately measure 
nanosecond FRET events between two fluorescently labeled proteins within a cell than traditional 
FRET because it measures the fluorescence lifetime of the donor independent of the local 
concentrations of donor and acceptor fluorophores (Becker et al., 2004).  
Previous studies of annexin proteins using FRET and other fluorescence techniques have revealed 
the ways different types of annexins interact with anionic phospholipids. FRET is used to identify 
the extent of the interaction between two proteins, which surfaces they use to make contact, and 
the spatial location of two proteins in relation to each other. The residues near the N-terminal end 
are unique to each annexin protein, therefore different annexins interact with anionic phospholipids 
differently. 
 
Figure 1.1: (A, left) the proposed model for membrane bridging of ANXA2 in a calcium-dependent manner, ( B, right) the 
proposed model for membrane bridging of ANXA2 in a proton-dependent manner. (Zibouche, Vincent, Illien, Gallay, & Ayala-
Sanmartin, 2008) 
In 2008, Zibouche et al. found a direct interaction between the N-terminal domain of ANXA2 and 
POPS/POPC vesicles without large structural changes in the core domain. They also discovered 
interactions between the N-terminal domains of adjacent ANXA2 proteins that were not in contact 
with the membrane as well as alterations in ANXA2 organization as a result of high Ca2+ 
concentration (Fig. 1.1). In 2008, Ayala-San-Martin et al. (2008) further supported these findings. 
Interestingly, Ayala-San-Martin et al.  found that regardless of the lipid composition used (POPC, 
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POPS, PE, and cholesterol), neighboring ANXA2 N-terminal domains interacted in the presence 
of lipids and calcium, but not in the absence of lipids, or in solutions with lipid lacking calcium. 
In contradiction to these findings, Patel et al. (2005) found that in the presence of POPC/POPS 
phospholipids (0.1mM) and calcium chloride (0.5mM) at pH 7.4, ANXA2 does not self-associate 
at the N-terminal residue. In some experiments, they observed a small change in the acceptor of 
ANXA2 upon membrane binding which they believe was due to chance interactions of a donor 
and acceptor.  
These studies did not look at the effect of phosphatidylinositol-4,5-diphosphate (PI(4,5)P2) on self-
association. In the presence of PI(4,5)P2ANXA2 has been shown to link adjacent GUVs and to 
induce membrane indentations (Drücker, Pejic, Galla, & Gerke, 2013). A study performed by Illien 
et al. (2012), characterized the role of calcium in causing ANXA2 to aggregate membranes 
containing PI(4,5)P2or PS in the presence and absence of cholesterol. PI(4,5)P2-containing 
membranes required higher calcium ion concentrations than POPS-containing membranes to cause 
half maximal membrane bridging by ANXA2, suggesting that in the presence of PI(4,5)P2, 
ANXA2 may experience structural changes of the N-terminal residue or the calcium-binding sites 
on the core domain. 
In this paper, FRET was used to determine whether the N-terminal residues of lateral ANXA2 
self-associate in the presence and absence of 100nm vesicles comprised of varying concentrations 
of PI(4,5)P2, POPC, and POPS. The singular exposed cysteine residue on the N-terminal domain of 
ANXA2 was labeled with AlexaFluor C5 Maleimide 488 (donor) fluorescent dye and AlexaFluor 
C5 Maleimide 568 (acceptor) fluorescent dye, then lipid or CaCl2 titrations were performed.  
This research was intended to provide a platform for future ANXA2 characterization studies as 
well as to complement existing data regarding the interactions of the N-terminal residue of 
ANXA2. Additionally, this research should expand current understanding regarding membrane 
domain formation by peripherally associated proteins.  
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CHAPTER 2—BACKGROUND  
This background begins by providing a brief summary of the important role the plasma membrane 
plays in cellular processes (Section 2.1). In Section 2.2, the role of membrane domains and 
membrane proteins, particularly peripheral membrane proteins, in mediating cellular processes 
through lipid-protein and protein-protein interactions is discussed. Section 2.3 and 2.4 elaborates 
on the properties and role of annexins, a family of physiologically relevant peripheral membrane 
proteins. In Section 2.5, annexin A2, the most studied annexin regarding human health and disease, 
and the focus of this research paper, is described. Finally, in Section 2.6, the use of fluorescence 
microscopy techniques, such as Fluorescence Resonance Energy Transfer (FRET) and 
Fluorescence Lifetime Imaging Microscopy (FLIM), in protein-interaction studies is described.  
 
2.1 Membrane Domains 
 
Figure 2.1: Model of the plasma membrane (https://en.wikipedia.org/wiki/Biological_membrane) 
According to the fluid mosaic model developed by Singer and Nicholson, the plasma membrane 
forms a phospholipid bilayer which acts as a sea in which various proteins and carbohydrates float 
around (Fig. 2.1). The plasma membrane provides protection from the extracellular environment 
and it plays an important role in conveying cellular signals, transporting water and nutrients into 
cells, and exporting waste products outside of cells (Maxfield, 2002). Its role in signaling and 
transport is reliant on the formation of small, localized regions of membrane which contain lipid 
compositions and properties that differ from the surrounding bilayer, commonly known as 
membrane domains or lipid rafts. There are numerous types of membrane domains which serve 
diverse roles, characterized using techniques; such as, fluorescence microscopy, electron 
microscopy, fluorescence resonance energy transfer, and single-molecule tracking. Due to the 
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small size and dynamic nature of domains they are difficult to study and many questions remain 
regarding how they form and are maintained (McIntosh, 2015). 
2.2 Role of Peripheral Membrane Proteins 
The roles of proteins in modifying, maintaining, and forming lipid rafts/membrane domains is 
central to uncovering the roles of membrane domains and the signaling processes they facilitate. 
Proteins are needed to produce signals that elicit an intracellular or extracellular response. A 
review by Rossy et al. (2014) concluded that proteins serve an essential role in regulating 
membrane organization by exploiting a lipid’s biophysical properties, such as its charge, thereby 
stimulating organization (Rossy, Ma, & Gaus, 2014). The nature of the domain is characterized by 
its chemical composition and physical properties as well as the features of the proteins and other 
macromolecules it interacts with (Jacobson, Mouritsen, & Anderson, 2007). Studying how 
peripheral membrane proteins interact with membrane domains can uncover the role a specific 
membrane domain serves in mediating the function of a given protein and vice versa (Rossy et al., 
2014).  
When peripheral membrane proteins interact with the plasma membrane they can alter lipid 
composition in three ways resulting in (Luckey, 2014): 
(1) A homogeneous lipid mixture: causes no lipid reorganization 
(2) De-mixing according to the law of mass action: Redistribute lipids with no preferential 
interaction  
(3) Total de-mixing: concentration of specific lipids in a domain that binds protein 
In turn, lipids can alter the folding, structure, and organization of membrane and amphitrophic 
proteins which influences protein function and interactions with the membrane. Lipids can 
function in metabolic signaling and they play a role in the post-translational modification of some 
proteins. Lipids have varied chemical makeups and can work cooperatively with neighboring lipids 
of differing types to influence cellular processes (Bogdanov, Mileykovskaya, & Dowhan, 2008).  
Protein-lipid interactions are necessary because membrane proteins oftentimes require lipids for 
activity or to bind to or insert itself into the plasma membrane (Luckey, 2014). Protein recruitment 
to the membrane and the activation of signaling cascades oftentimes result from protein binding 
to a specific class of lipid (Loura, Prieto, & Fernandes, 2010).  Adjacent membrane lipids that do 
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not bind proteins can also interact with peripheral membrane proteins, modulating these 
interactions (Glomset, 1999). When proteins bind membrane surfaces this can facilitate further 
changes in the structure and function of the protein. Groups of proteins that concurrently bind to a 
membrane surface can also interact with each other creating a complex network of membrane-
related events (Glomset, 1999).   
 
2.3 Annexins 
Annexins are an ancient, conserved family of peripheral membrane proteins which are useful to 
study because they are widely expressed in plants and animals. These proteins are soluble and 
hydrophilic (Gerke & Moss, 2002). Humans have twelve types of annexin proteins which all serve 
different, but related, functions in the body.  Structurally, annexins have four or eight super helical 
repeats which form right-handed binding sites for calcium ions. Annexins also have a carboxyl 
core domain which is shaped like a concave disk and an amino, N-terminal, domain connected at 
the concave portion of the disc facing the cytosol (Fig. 2.3), (Gerke et al., 2005).  
 
Figure 2.2: Structure of ANXA2 bound to the membrane (top), and the ribbon diagram of ANXA2 (bottom) 
2.3.1 Core Domain 
The core domain reversibly binds calcium and anionic phospholipids. Structurally, the core 
domain has four homologous domains which each contain five α-helices (A-E). The AB and DE 
domains are connected by loops that form an endonexin fold, which is considered the signature 
amino acid sequence of annexins (Lizarbe, Barrasa, Olmo, Gavilanes, & Turnay, 2013), 
Annexins: linking Ca
2+
 signalling to membrane dynamics 
Volker Gerke, Carl E. Creutz & Stephen E. Moss 
Nature Reviews Molecular Cell Biology 6, 449-461 (June 2005) 
doi:10.1038/nrm1661 
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(Bharadwaj et al., 2013). The lipid and calcium binding sites protrude from the convex side of the 
core domain facing the plasma membrane (Drücker, Pejic, Grill, Galla, & Gerke, 2014). In the 
presence of calcium, the ANXA2 core domain can connect two membrane surfaces and aggregate 
lipid vesicles (Drücker et al., 2014). 
 
2.3.2 N-terminal Domain 
Annexins also have unique N-terminal interaction domains which contain sites for post-
translational modification and protein-protein interactions (Valapala & Vishwanatha, 2011) The 
N-terminal domain influences the stability and function of annexins and it is capable of binding 
cytosolic protein ligands, such as those of the S100 family (Valapala & Vishwanatha, 2011). The 
N-terminal domain also regulates the specific function of individual annexins. The N-terminal 
domain of different annexins vary in length and sequence (Lizarbe et al., 2013). It is believed 
that shorter amino terminal domains of smaller annexin proteins can alter calcium-dependent 
binding of phospholipids by stabilizing or weakening different conformational changes of 
annexins (Gerke & Moss, 2002). Annexin A2 (ANXA2) has a medium-sized N-terminal domain 
containing 30 amino acids as well as sites for phosphorylation and proteolysis (Liu, 1999). 
 
2.4 Physiological Relevance of Annexins 
Over the years, many researchers have conducted experiments in order to elucidate the 
biochemical properties and the subcellular localization of annexins (Rescher & Gerke, 2004). 
These experiments highlighted the physiological relevance of annexins, which are involved in 
many important cellular processes. For example, annexins are implicated in membrane transport 
(including ion transport, endocytosis and exocytosis), immune functions, redox regulation, cell-
cell adhesion, cellular signaling, and the regulation of membrane cytoskeleton contacts (Drücker 
et al., 2014), (Bharadwaj et al., 2013). Figure 2.3, shows the various roles annexins are believed 
to play inside and outside of cells (Lizarbe et al., 2013). These cellular processes have important 
implications in human health and disease. Annexins are used as early markers for apoptosis and 
are overexpressed in certain tumor cells (Luckey, 2014). The term “annexinopathy” was coined in 
1999 to recognize the role annexins play in human pathophysiology as they mediate diverse, 
interconnected cellular functions (Hajjar, 2015).  
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Figure 2.3: Function of annexin proteins in cells ( Lizarbe et al., 2013), (Hajjar, 2015), (Luckey, 2014). 
2.5 Physiological Relevance of Annexin A2 
According to Dr. Hajjar, Weill Cornell Medical College, “Annexin A2 (ANXA2) is arguably the 
most extensively investigated annexin regarding health and disease” (Hajjar, 2015). ANXA2 has 
been found in endothelial cells, monocytes, macrophages and many cancer cells (Bharadwaj et al., 
2013). In cancer cells, ANXA2 and its binding partners, such as S100A10, have been shown to 
promote metastasis by remodeling actin and regulating cytoskeleton structures (Lokman et al., 
2011). As a mediator of the plasminogen activator system, ANXA2 also plays a role in regulating 
thrombolysis, fibrinolysis, and wound healing (Lokman et al., 2011).  
The N-terminal domain can regulate the function of ANXA2 by altering calcium affinities at 
protein-interaction sites in the core domain, also as a direct result of tyrosine phosphorylation 
(Gerke et al., 2005). Membrane interactions of ANXA2 also play a significant role in mediating 
cellular functions. Annexin A2 binds to and aggregates vesicles containing the anionic 
phospholipids phosphatidic acid, phosphatidylserine, and phosphatidylinositol; but not vesicles 
containing phosphatidylcholine, phosphatidylethanolamine, or cholesterol (Bharadwaj et al., 
2013). When ANXA2 associates with cholesterol and phosphatidylinositol 4,5-bisphosphate 
(PI(4,5)P2) rich-domains, it promotes the formation and influences the dynamics of those domains. 
Cholesterol appears to improve the membrane-binding affinity of ANXA2 by aiding the formation 
of domains containing high concentrations of anionic phospholipids (Bharadwaj et al., 2013). 
Endocytosis
Exocytosis
Ion transport
Vesicle trafficking
Lipid raft formation
Thrombolysis
Fibrinolysis
Wound healing
Calcium signaling
Lipid-mediated 
signaling
Metastasis
Actin assembly
Nuclear functions
Cytoskeleton 
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There are still a lot of questions regarding the mechanism by which domains form and the 
functional role these lipid domains serve when bound to ANXA2 (Valapala & Vishwanatha, 2011). 
By uncovering this lipid-protein puzzle, much can be learned about the function of ANXA2. 
2.6 Fluorescence Microscopy 
Fluorescence microscopy is a commonly used method for protein-interaction studies (Yan & 
Marriott, 2003). Types of fluorescence microscopy include: Fluorescence resonance energy 
transfer (FRET), fluorescence lifetime imaging microscopy (FLIM), and fluorescence correlation 
spectroscopy (FCS). The advent of new fluorescent probe technology and labeling strategies has 
improved the use of fluorescence in various biological applications. Fluorescence spectroscopy is 
capable of making time-resolved measurements which can be used to characterize protein 
dynamics and to study conformational changes (Yengo & Berger, 2010).  
2.6.1 FRET 
FRET is used to measure the non-radiative energy transfer which occurs when a high-energy donor 
fluorophore excites a lower-energy acceptor fluorophore. In order for this interaction to occur 
(Piston & Kremers, 2007):  
(1) The emission and absorption spectra of the two fluorophores must overlap (Fig. 2.4) 
             (2) The fluorophores must be separated by a distance of 10-100 angstroms 
 (3) The transition dipoles of the fluorophores must be oriented parallel to each other 
The likelihood a FRET transfer will occur for a given acceptor and donor is described by the 
Forster distance, which is the distance the donor is from the acceptor when there is a 50% 
possibility of energy transfer which results in donor inactivation (Loura et al., 2010).  
17 
 
 
Figure 2.4: The overlap of the donor and acceptor fluorophores required for FRET transfer 
(http://www.calctool.org/CALC/chem/photochemistry/fret) 
FRET is useful in determining protein-protein interactions which result from changes in affinity 
between two fluorescently labeled proteins or changes in binding conformation (Piston & Kremers, 
2007). FRET can identify the extent of the interaction between two proteins, which surfaces they 
use to make contact, and the spatial location of the two proteins in relation to each other 
(Mendelsohn & Brent, 1999). Theoretically, FRET can be used to study interactions between 
proteins in any cellular compartment (Mendelsohn & Brent, 1999). When a FRET transfer occurs 
the intensity and lifetime of the donor fluorophore decrease while the intensity of the acceptor 
fluorophore increases. FLIM can be used to improve the quality of FRET-based imaging of 
protein-protein interactions within cells (Yan & Marriott, 2003). 
2.6.2 FLIM 
FLIM is used to measure nanosecond FRET events between two fluorescently labeled proteins 
within a cell (Yan & Marriott, 2003). FLIM works by recording images in terms of the fluorescence 
lifetime of the donor independent of the local concentrations of donor and acceptor fluorophores 
(Becker et al., 2004). Since the concentration of the fluorophore is inessential, FLIM can directly 
study phenomena involving energy transfer. Fluorescence lifetime is a direct indicator of the 
energy transfer rate from donor to acceptor (Becker et al., 2004). 
2.6.3 FCS 
FCS is a high resolution spatiotemporal analysis technique which measures fluctuations in thermal 
equilibrium which occur when single molecules alter their fluorescence intensity or leave the 
observation lens. Using a sensitive confocal microscope, it is possible to determine the local 
molecular concentration, mobility coefficients (such as translational and rotational mobility), the 
viscosity of the solution, and the size or shape of the molecules passing through the lens. Rate 
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constants of intermolecular and intramolecular reactions of fluorescently-labeled molecules can 
also be measured. If the brightness (η) is known, it is also possible to quantify the rate of 
fluorescence quenching. This method functions at nanomolar concentrations of a biological sample 
by using principles of relaxation analysis. The strength and duration of fluctuations are measured 
by autocorrelating the intensity signal with the time, which measures the deviation in signal over 
time (Schwille, 2005). Collectively, these fluorescent techniques are useful in studying protein-
protein and protein-lipid interactions, but there are other methods, such as cross-linker 
experiments, co-immunoprecipitation and co-pelleting assays, which can also elucidate the 
behavior of ANXA2 in vivo and in vitro.  
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CHAPTER 3—CO-PELLETING ASSAYS AND CROSS-LINKER EXPERIMENTS 
ELUCIDATE THE ROLE OF ANXA2 DIMERIZATION 
This chapter begins with a brief introduction (3.1) about the potential for ANXA2 to dimerize in 
the presence of calcium, the role of dimerization, and the role of the N-terminal domain in these 
interactions. Then, the Materials and Methods (3.2) describes how the Sulfo-EGS cross-linker 
experiments and liposome co-pelleting assays were performed on ANXA2 WT and the ANXA2 
10X and 6X mutants. Finally, Section 3.3 discusses the results of these experiments.  
3.1 Introduction  
Annexin A2 (ANXA2) is a peripheral membrane protein which binds anionic phospholipids in a 
calcium-dependent manner. Alterations in phospholipid and calcium binding allows ANXA2 to 
function in vesicle trafficking, lipid raft formation, signaling, and cytoskeletal interactions 
(Bharadwaj et al., 2013). By studying the functional mechanism by which ANXA2 influences 
these many processes, we can learn how these peripheral membrane proteins play important roles 
in human health and disease. 
In 2004, Rosengarth and Luecke crystallized full length ANXA2 in order to determine the 
propensity of ANXA2 to induce membrane aggregation by forming a multimeric state. Their 
research revealed that in the presence of calcium, ANXA2 dimerizes at repeat 3 in an “upside-
down” fashion in which the concave side of one monomer faces the convex side of another 
monomer, as shown in Fig. 3.1. They identified the residues that make up the dimer interface using 
protein crystallography.  
 
Figure 3.1: “Arrangement of the full-length ANXA2 dimer in the presence of calcium. The dimer contact is established through 
repeat 3” (Rosengarth & Luecke, 2004). 
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In order to evaluate the functional purpose of dimerization in altering calcium binding affinities 
and protein-protein interactions, two mutant forms of ANXA2 were developed by the Gerke lab. 
ANXA2 6X, has 6 mutations at the salt bridges and calcium binding sites which make up the dimer 
interface: K81A, E189K, K206A, R196S, E219K, and K212S. The mutations are present on region 
3, except K81A which is present on Region 1 where it has been shown to hydrogen bond to a 
neighboring ANXA2 dimer. These mutations convert polar amino acids into non-polar amino acids 
or positively charged amino acids into negatively charged amino acids which is intended to disrupt 
the salt bridges, preventing dimerization. The primers used for mutation can be found in Appendix 
A (8.1).  
The second mutant form of ANXA2, ANXA2 10X has all of the mutations found in ANXA2 6X 
plus an additional 4 mutations: R36S, V53A, T54A, and K328A. These additional mutations also 
convert polar amino acids to nonpolar amino acids or alter the charge of the amino acid. The R36S 
mutation is next to the K81A mutation in Region 1, and both are believed to form a second region 
promoting dimerization in the wild type. The V53A, T54A, and K328A mutations were added to 
disrupt calcium-binding sites. A visual of the ANXA2 6X and 10X mutations (PDB ID 1XJL) is 
shown in Fig. 3.2 ANXA2 10X should prevent dimerization in the core domain, unless the N-
terminal domain which could not be characterized through protein crystallography, plays a role in 
facilitating dimerization.  
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Figure 3.2: ANXA2 PDB ID 1XJL with 6x and 10x mutations highlighted in CPK atom and bond format. The 6x mutations are teal 
and the additional 10x mutations are black. The N-terminal residue is the periwinkle loop after the 36Glu residue (Protein 
Workshop). 
Currently, the role of the N-terminal domain in calcium-dependent membrane bridging is 
ambiguous (Ayala-San Martin Zibouche, 2008). This research was intended to elucidate the 
importance of dimerization in membrane bridging and the role of the N-terminal domain in this 
process by comparing the calcium-dependent binding of these mutants to the wild type by 
performing liposome co-pelleting assays and by performing Sulfo-EGS (ethylene 
glycolbis(succinimidylsuccinate)) cross-linking experiments to see if the N-terminal domain can 
form similar protein-protein interactions to the wild type.  
3.2 Materials and Methods 
3.2.1 ANXA2 10X, 6X, WT Expression  
Glycerol stocks of ANXA2 WT, 10x, and 6x inserted into an E.coli BL21 (DE3)pLysS vectors, 
were used to inoculate an LB culture containing  150mM ampicillin. The cultures were grown to 
OD600 of 0.6 at 37°C, induced with 1mM IPTG, incubated in the shaker for 4 hours (250rpm, 
37°C), and then chilled in the cold room for 30 minutes. The cell cultures were centrifuged at 
5,000xg for 10 minutes at 4°C. The supernatant was discarded and the pellets were re-suspended 
in lysis buffer (50mM imidazole, 300mM NaCl, 10mM MgCl2, 2mM DTT, 1 capsule Complete 
Protease Inhibitor EDTA-free, pH 7.4, 3 mL/g of wet pellet), and stored in -80°C.  
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3.2.2 ANXA2 10X, 6X, WT Purification 
The protocol for the purification of ANXA2 WT can be found in Chapter 5 Section 3. The ANXA2 
6X and 10X are purified in a similar manner. For the specific details of the equipment used and 
the antibodies used for the Western blot, refer to see the Methods section “Expression and 
Purification of Recombinant ANXA2” and “Antibodies, Expression Constructs, Proteins, and 
Synthetic Peptides” in Drucker et al. (2013) Lipid segregation and membrane budding induced by 
the peripheral membrane binding protein annexin A2. 
3.2.2 Co-pelleting Liposome Assays 
3.2.2.1 Liposome Preparation 
Lipid samples were prepared according to the Avanti website1 and lipid concentration was verified 
by performing phosphate assays. The desired lipid composition and concentration was measured 
and the lipids were dried using a stream of nitrogen while gently heating the lipids on a hot plate. 
The lipid films were stored in a vacuum overnight, then re-suspended in the experimental buffer 
(PBS or MES), heated to 60°C, vortexed, and extruded through a 200nm polycarbonate filter using 
an extrusion kit. The 200nm liposomes were prepared in a 20:60:20 POPS: POPC: Cholesterol 
ratio with 1mg of total lipid in 1mL. In these experiments, 300uL of liposomes were added 
(300ug). 
3.2.2.2 Co-Pelleting Liposome Assay Protocol 
20-60ug of ANXA2 WT, 6X, or 10X was added to 300ug of 20:60:20 POPS: POPC: Cholesterol 
and 250mM CaCl2 which was brought to a volume of 250uL using MES or PBS buffer. The 
solution was incubated for 1hr at 4°C and placed in the Beckman Optima TL Ultracentrifuge at 
100,000rpm (96,600xg) at 4°C for 15min. The supernatant was collected and labeled as “Calcium 
1.” The pellet was re-suspended in 250uL of MES or PBS buffer containing 250mM CaCl2, 
incubated for 15min at 4°C, and then placed in the Beckman Optima TL Ultracentrifuge at 
100,000rpm (96,600xg) at 4°C for 15min. The supernatant was collected and labeled as “Calcium 
2.” The pellet was re-suspended in 250uL of MES or PBS buffer containing 5mM EGTA, 
incubated for 15min at 4°C, and then placed in the Beckman Optima TL Ultracentrifuge at 
100,000rpm (96,600xg) at 4°C for 15min. The supernatant was collected and labeled as “EGTA 
                                                          
1 https://avantilipids.com/ 
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1.” The pellet was re-suspended in 250uL of MES or PBS buffer containing 5mM EGTA and 
labeled as EGTA 2. All fractions were ran on a denaturing 15% SGS-PAGE gel and scanned using 
the LI-COR. 
3.2.3 Sulfo-EGS Cross-linker Experiments 
The ANXA2 WT, 6X, and 10X proteins were dialyzed against HEPES buffer (20mM HEPES, 
150mM NaCl, pH 7.4) and concentrated using an Amicon Ultra-4 Centrifugal Filter unit to a 
concentration of approximately 2mg/mL. The liposomes were prepared as described in Section 
3.2.2.1 using a ratio of DOPC: POPC: POPS: Cholesterol (20:40:20:20), and an overall lipid 
concentration of 1mg/0.3mL (3.34mg/mL). For each experiment, a control without cross-linker 
and liposomes was prepared, a control with EGTA without calcium, and a probe containing 
liposomes, cross-linker, and ANXA2 WT/6X/10X. 
Initially, the controls and the probe are prepared without the Sulfo-EGS cross-linker and incubated 
at room temperature for 45minutes on the rocker. The control without cross-linker of liposomes 
has 60ug ANXA2 WT/6X/10X, 1mM CaCl2, and is brought to a volume of 70uL with HEPES 
buffer. The EGTA control has 60ug ANXA2 WT/6X/10X, 100ug LUVs, 5mM EGTA, and is 
brought to a total volume of 70uL with HEPES buffer (including the volume of the cross-linker to 
be added later). The probe has 60ug ANXA2 WT/6X/10X, 100ug LUVs, 1mM CaCl2, and is 
brought to a total volume of 70uL with HEPES buffer (including the volume of the cross-linker to 
be added later). 
After 45 minutes, the Sulfo-EGS cross-linker was heated to 60°C and 0.3mM was added to the 
EGTA control and the probe. The controls and probe were then incubated at room temperature for 
an additional 45minutes on the rocker, then 15uL 5x SDS buffer without beta-mercaptoethanol 
was added to the controls and the probe. 3uL of 100mM EGTA was added to the probe and the 
samples were all left to sit at room temperature for 10min. 30uL of each sample was ran on a native 
10% SDS-PAGE gel. The gel was rinsed 3x with water and stained with 30mL ThermoFisher 
Imperial Protein Stain for 2 hours. The gel was de-stained with Millipore water. The gels were 
scanned with a LI-COR. 
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In order to prevent the oxidized cysteine double bond which leads to the appearance of both the 
ANXA2 monomer and dimer in the control, the wild type ANXA2 was alkylated for 30minutes 
before it was ran on a 15% SDS-PAGE gel. 
3.3 Results and Discussion  
This section begins by discussing the results of the co-pelleting assays and ends by discussing 
the results of the Sulfo-EGS cross-linker experiments. 
Figure 3.3: Co-pelleting liposome assays. Each experiment was performed in PBS buffer using 20ug ANXA2 6x, 60ug ANXA2 10X, 
40ug ANXA2 WT, 250mM CaCl2 in the calcium fractions, and 5mM EGTA in the EGTA fractions in a total volume of 450Ul. For a 
detailed description of each fraction refer to the Methodology. 
Co-pelleting liposome assays were performed in order to assess the ability of wild type ANXA2 
and the ANXA2 6X and ANXA2 10X mutants to reversibly bind anionic phospholipids in a 
calcium-dependent manner; a property of all forms of annexins, as shown in Fig. 3.3. By adding 
an excess of calcium chloride (250mM) in the presence of 100ug of 200nm liposomes containing 
20:60:20 POPS: POPC: Cholesterol, the majority of the ANXA2 used in these experiments (20-
60ug) was anticipated to bind liposomes in the presence of calcium and thus will be present in the 
pellet after the solution is centrifuged at 100,000rpm. 200nm vesicles were favorable to smaller 
vesicles because the larger size allows them to pellet at a lower speed. Upon the addition of EGTA, 
the ANXA2 protein should unbind the liposomes and be free in solution; allowing ANXA2 to 
show up in the supernatant after centrifugation.  
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In the first set of co-pelleting assays varying concentrations of ANXA2 were used to determine 
how much protein can bind 100ug of 20:60:20 POPS: POPC: Cholesterol liposomes. The co-
pelleting experiment with 40ug of ANXA2, showed that the majority of the ANXA2 WT protein 
was bound to liposomes in the presence of calcium and upon the addition of EGTA, a chelator 
which preferentially targets divalent calcium ions, approximately half of the ANXA2 WT protein 
was released and half remained bound. The presence of large ANXA2 WT in the pellet after EGTA 
addition (5mM), suggests that more EGTA is needed to effectively chelate all of the Ca2+ ions, but 
that the ANXA2 WT can effectively bind liposomes in the presence of Ca2+ ions. 
In comparison to the ANXA2 WT co-pelleting assay, the ANXA2 6X behaved similarly, although 
the ANXA2 6X experiment only had 20ug ANXA2 6X. There was a negligible amount of ANXA2 
6X present in the first calcium fraction, and a small amount of ANXA2 6X was present in the 
second calcium fraction. The presence of ANXA2 6X in the second calcium fraction suggests that 
a small amount of the protein may have been damaged during resuspension and could no longer 
bind liposomes in a calcium-dependent manner. Upon EGTA addition, the majority of the ANXA2 
6X was present in the supernatant, which indicates that ANXA2 6X binds reversibly to anionic 
phospholipids in the presence of calcium. The reduction in the amount of ANXA2 6X in the EGTA 
2 fraction likely occurred because there was less ANXA2 6X present in this experiment than in 
the wild type. These findings suggest that the mutated residues did not significantly alter the ability 
of ANXA2 6X to bind lipids.  
In order to further verify these findings, additional co-pelleting experiments were performed using 
20ug of ANXA2 6X to replicate the cross-linker experiment in Fig.3.4 and another co-pelleting 
assay with 40ug of ANXA2 6X which exactly mimics the experimental conditions for the ANXA2 
WT co-pelleting assay in Fig. 3.3. The 40ug ANXA2 6X co-pelleting assay appeared very similar 
to the 20ug ANXA2 6X co-pelleting assay.  
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Quantification of each band size using the LI-COR showed that in the 40ug experiment 3.5% 
ANXA2 6X (1.49ug/42.29ug) appeared in the first calcium fraction, 4.5% ANXA2 6X 
(1.90ug/42.49ug) appeared in the second calcium fraction, 74.4% ANXA2 6X (31.61ug/42.49ug) 
appeared in the first EGTA fraction, and 17.6% ANXA2 6X (17.49ug/42.49ug) appeared in the 
second EGTA fraction. In the 20ug ANXA2 6X experiment 2.7% ANXA2 6X (0.55ug/20.08ug) 
appeared in the first calcium fraction, 4.88% ANXA2 6X (0.98ug/20.08ug) appeared in the second 
calcium fraction, 77.1% ANXA2 6X (15.49ug/20.08ug) appeared in the first EGTA fraction, and 
15.2% ANXA2 6X (3.06ug/20.08ug) appeared in the second EGTA fraction. 
Figure 3.4: ANXA2 6X Co-pelleting liposome assay. Each experiment was performed in MES buffer using 250mM CaCl2 in the 
Calcium fractions and 5mM EGTA in the EGTA fractions. For a detailed description of each fraction refer to the Methodology. 40ug 
ANXA2 6X experiments Left to Right: 1.49ug ANXA2 6x in Calcium 1, 1.90ug in Calcium 2, 31.61ug in EGTA 1, and 7.49ug in EGTA 
2. 20ug ANXA2 6X experiments Left to Right: 0.55ug ANXA2 6x in Calcium 1, 0.98ug in Calcium 2, 15.49ug in EGTA 1, and 3.06ug 
in EGTA 2. 
In comparison to the ANXA2 W co-pelleting assay, it appears that the ANXA2 6X is held more 
loosely by the membrane, allowing more of the ANXA2 6X mutant to become unbound from the 
membrane upon the addition of EGTA than the wild type. 
Comparatively, the ANXA2 10X mutant bound the liposomes less effectively than the wild type 
and 6X mutant. The reduced binding was likely due to the presence of higher amounts of ANXA2 
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10X (60ug). The EGTA fractions contained the majority of the ANXA2 10X protein suggesting 
that ANXA2 10X also retained the ability to reversibly bind anionic phospholipids in the presence 
of calcium, even though additional calcium-binding sites were mutated in addition to the mutations 
present in the ANXA2 6X mutant. In future experiments, equivalent concentrations of the mutants 
and wild type should be studied and higher EGTA concentrations should be used to reduce the 
amount of ANXA2 WT/6X/10X in EGTA fraction 2. Overall though, these findings support that 
these mutations did not fully destroy the function of ANXA2, and thus they can be used for further 
experimentation. 
In order to understand how these mutations affected the ability of ANXA2 to dimerize and form 
protein-protein interactions, Sulfo-EGS cross-linker experiments were performed as shown in Fig. 
3.5. According to the ThermoFisher Scientific website2, Sulfo-EGS is a water-soluble cross-linker 
which targets primary amine groups via a sulfo-NHS ester which is reactive at both ends and forms 
a 12-atom spacer arm. The lipids used in these experiments do not have primary amine groups, 
therefore only proteins which are within 12-atoms of each other will cross-link.  
The ANXA2 WT showed numerous cross-linking protein bands in the probe lane of the native 
SDS-PAGE gel. The probe contained 60ug ANXA2 WT, 100ug liposomes, 1mM CaCl2, and 
0.3mM Sulfo-EGS cross-linker. There were no noticeable cross-linking bands in the  in EGTA 
control or the control without cross-linker and liposomes. Cross-linking upon the addition of lipids 
and calcium suggests that when ANXA2 WT binds to anionic phospholipids, this produces a 
conformational change promoting further ANXA2 WT interactions.  
Additionally, there are two protein bands present in the EGTA control and the control without 
cross-linker and liposomes because the N-terminal cysteine forms a double bond when oxidized 
which leads to additional cross-linking due to oxidative products. The majority of the ANXA2 WT 
appears around 70kDa, suggesting that when oxidative products do not inhibit dimerization, 
ANXA2 WT preferentially dimerizes.  
                                                          
2 https://www.thermofisher.com/order/catalog/product/21566 
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The ANXA2 10X behaves similarly to the ANXA2 WT, but the ANXA2 10X appeared to cross-
link more strongly with fewer bands than the wild type. ANXA2 10X had approximately 6 highly 
visible protein bands from 11-35kDa in size, while the ANXA2 WT over 10 bands which were 
very faint after alkylation. In the control without cross-linker and liposomes, there are a few faint 
bands which suggest the presence of either small amounts of contamination or small amounts of 
protein degradation. There is also a faint band at 55kDa in the control without cross-linker and 
liposomes that is not present in the EGTA control, suggesting that calcium may produce 
conformational changes in the ANXA2 10X mutant, producing this additional band. The presence 
of equally strong protein bands at 35kDa and 70kDa indicates that ANXA2 can still dimerize even 
Figure 3.5: Sulfo-EGS Cross-linker Experiments. Top Native SDS-PAGE gels LI-COR scan, Bottom: Native SDS-PAGE gels in black and white. ANXA2 WT Lanes Left to 
Right: Protein Color Standard ladder, unalkylated control without cross-linker, empty lane, unalkylated EGTA control, unalkylated probe, Protein Color Standard 
ladder, alkylated control without cross-linker, alkylated EGTA control, alkylated probe. ANXA2 10X: Protein Color Standard ladder, control without cross-linker, 
EGTA control, probe. ANXA2 6X: Protein Color Standard ladder, Control without cross-linker, EGTA control, T1 probe, T2 probe. 
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though there are mutations in the dimerization site, suggesting that the N-terminal domain may 
play a stronger role than the residues in Region 1 and 3 of ANXA2 in promoting dimerization. 
Compared to ANXA2 WT, ANXA2 10X did not dimerize as efficiently which may have been due 
to the presence of more oxidative products causing a higher amount of cysteine double bonds, 
inhibiting dimerization. Future experiments should be performed in which the ANXA2 is alkylated 
to see how this effects the ratio of monomer to dimer.  
Comparatively, the ANXA2 6X mutant was unaffected by the presence of the cross-linker, 
calcium, or lipids, suggesting that ANXA2 6X may have degraded prior to experimentation, likely 
after concentration and dialysis; suggesting that the mutation resulted in a less stable protein. The 
liposome assays indicated that ANXA2 binds anionic phospholipids in the presence of calcium, 
thus the ANXA2 6X was expected to undergo a conformational change, producing cross-linked 
ANXA2 proteins. There is a small possibility that ANXA2 does not change its protein-protein 
interactions upon membrane binding due to the nature of its mutations and is constantly shifting 
conformation due to lowered stability, but it would be expected that the ANXA2 10X mutation 
would have behaved similarly, if not less efficiently. Interestingly, ANXA2 6X still harbored a 
strong propensity to dimerize, indicating that the N-terminal domain must facilitate this 
interaction. In the future, the ANXA2 6X should be re-purified and these experiments should be 
repeated with and without alkylation. Overall, these findings support the notion that the N-terminal 
domain might play a role in ANXA2 dimerization. In order to further study the propensity of the 
N-terminal domain of ANXA2 to promote lipid aggregation and the formation of lipid rafts via 
self-association, the research aim and project approach were developed. 
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CHAPTER 4—ANXA2 MEDIATED LIPID CLUSTERING  
Chapter 4: Research Aim and Project Approach, begins by discussing the importance of 
characterizing the interactions of ANXA2 with anionic phospholipids (4.1). Section 4.2 discusses 
the scope and aim of this research. Section 4.3 provides a review of related experiments conducted 
by others to provide the reader with an understanding of different methods which have previously 
been used to characterize the function of ANXA2. Lastly, Section 4.4 provides an overview of the 
project approach which includes the hypotheses to be tested and the specific aim of each 
experiment. 
4.1 Importance of Characterizing the Interactions of ANXA2 with Anionic Phospholipids 
ANXA2 is a physiologically relevant protein implicated in wide ranging cellular processes such 
as cell motility, tumorigenesis, osteoclast formation, fibrinolysis, membrane transport, and cellular 
signaling (Valapala & Vishwanatha, 2011). The role of this protein in human health and disease is 
far-reaching but its exact functional role in these processes is unknown. According to Blackwood 
et al. (1990), researching the ability of ANXA2 to bind to cellular membranes and calcium has 
elucidated the role this protein plays in mediating endocytosis, exocytosis, and other membrane 
trafficking events (Blackwood & Ernst, 1990).  
As evidenced by a review by Gerke & Moss (2002), there is still much to be learned in order to 
determine the physiological importance of the calcium-dependent phospholipid and membrane 
binding of ANXA2 (Gerke & Moss, 2002). It is known that when ANXA2 associates with the 
plasma membrane or early endosomes, the core domain forms a compact disk whose convex side 
associates with membrane phospholipids and the concave portion is oriented away from the 
membrane (Fig. 2.2). ANXA2 binds anionic phospholipids at evolutionarily conserved annexin 
repeats within the core domain (Hedhli et al., 2012). ANXA2 binding to the plasma membrane is 
believed to cause cytosolic anionic phospholipids to cluster. The clustering activity of anionic 
phospholipids has a number of possible mechanisms. For example, when ANXA2 binds to the 
plasma membrane, this could promote self-association, promoting further clustering, aiding the 
development of a domain primarily comprised of anionic phospholipids. This clustering activity 
is believed to produce membrane domains or lipid rafts which function as signaling platforms 
(Gerke & Moss, 2002). Understanding the creation and function of these signaling platforms could 
provide useful clues about the importance of ANXA2 in signal transduction pathways. 
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The ability of annexins to self-associate and to bind anionic phospholipids differs between 
different forms of annexins and the nature of how these two processes function together is largely 
unknown. In 1991, research performed by Zaks and Creutz, suggested that calcium concentrations 
may dictate the relationship between self-association and phospholipid binding. At low 
concentration of calcium ions, membrane binding may require self-association. While at higher 
calcium ion concentrations, annexins likely monomerically bind two membranes. Self-association 
may be an evolutionary advantage allowing annexins to aggregate at membrane contact sites, 
strengthening this interaction (Zaks & Creutz, 1991). Other researchers, such as Hong et al. (1982), 
discount the notion of self-aggregation, preferring the idea that each annexin has multiple 
membrane binding locations to cross-link membranes (Hong, Düzgüneş, Ekerdt, & 
Papahadjopoulos, 1982). Differing annexins have variable N-terminal domains, and it has been 
found that some annexins have the propensity to self-associate while others do not.  
Another interesting feature of ANXA2 is its capacity to aggregate membranes. When ANXA2 
binds membranes comprised of anionic phospholipids, annexins A1, A2, A4, A6, and A7 
participate in membrane vesicle aggregation (Gerke & Moss, 2002). Blackwood et al. (1990) has 
shown that the amino-terminus of ANXA2 plays an important role in aggregating cellular 
membranes. Structurally, the role of the N-terminus in membrane aggregation is difficult to explain 
because the phospholipid binding sites are on the opposite side of ANXA2 (Blackwood & Ernst, 
1990). A proposed method for membrane vesicle aggregation, is the self-association of ANXA2 
molecules already bound to different portions of cellular membrane.  
The heterotetrameric form of ANXA2 promotes self-association and consequently aggregates 
membranes more efficiently than monomeric ANXA2. The heterotetramer also has an increased 
phospholipid binding affinity (Hedhli et al., 2012). ANXA2 forms a heterotetramer by 
preferentially binding to S100A10, also known as p11, a calcium-binding protein with an EF-hand 
motif (Hedhli et al., 2012). The heterotetramer form of ANXA2 aggregates membranes at 
micromolar calcium levels which are much lower than the calcium concentrations required for the 
monomer form (Gerke & Moss, 2002). A similar form of annexin, annexin A1, binds calcium, 
which induces a conformational change making the amino-terminal domain accessible for 
heterotetramer formation (Fig. 4.1), (Rescher, Zobiack, & Gerke, 2000). Zibouche et al. (2008), 
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has shown that ANXA2 associates with the membrane without any significant changes in the 
structure of the core domain (Zibouche, Vincent, Illien, Gallay, & Ayala-Sanmartin, 2008). 
 
 
Figure 4.1: Annexin A1 Heterotetramer Formation. Annexin A1 binds calcium, inducing a conformational change which makes 
the amino-terminal domain accessible for heterotetramer formation (Rescher, Zobiack, & Gerke,2000) 
ANXA2 has been shown to form membrane-cytoskeleton interactions in addition to its membrane-
membrane interactions. These calcium-dependent interactions assist numerous biological 
processes such as membrane trafficking and the maintenance of the shape of cells and organelles 
(Jost, Zeuschner, Seemann, Weber, & Gerke, 1997). The calcium-dependent binding of ANXA2 
is reversible, and calcium chelating agents, such as EGTA, can be used to release annexins from 
binding anionic phospholipids. Conversely, the absence of calcium should nullify the interactions 
between ANXA2 and anionic phospholipids. 
Understanding the importance of calcium in the function of ANXA2 can yield an array of 
important information. Calcium ions serve as secondary messengers in a number of cellular 
processes, enabling extracellular calcium signals to produce an intracellular response and vice 
versa. Regulation of intracellular Ca2+ concentrations helps to maintain this calcium signaling 
network. ANXA2 binds calcium ions within cells and is believed to participate directly in calcium 
signaling by creating conformational changes, and other altered cellular states as a result of 
calcium binding. The exact role of ANXA2 within the calcium signaling network still needs to be 
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determined (Gerke & Moss, 2002). There is evidence that ANXA2 can function in the absence of 
calcium under certain cellular conditions. For instance, Jost et al. (1997), found that at a neutral 
pH, ANXA2 binds endosomal membranes calcium independent. 
Cellular signaling is highly interconnected and it is often difficult to determine how multiple 
molecules interacting together elicit a particular cellular response in vivo. By working to 
understand how ANXA2 interacts with calcium and anionic phospholipids to facilitate cellular 
processes such as exocytosis and thrombolysis, in vitro, it is then possible to understand how the 
body works and why diseases such as antiphospholipid syndrome or acute promyelocytic leukemia 
are linked to mutations in the ANXA2 gene. 
By researching the protein-protein and protein-lipid interactions of ANXA2, its functional role in 
cellular processes can be elucidated. Protein and lipid interactions comprise most cellular events, 
and by understanding the spatiotemporal nature of the interaction, the reaction conditions required 
for interaction, and the result of the interaction it is then possible to determine the function of this 
interaction in the body. Different calcium concentrations, pH levels, and anionic phospholipid 
composition have been shown to alter ANXA2 interactions with anionic phospholipids both in 
vitro and in vivo (Zaks & Creutz, 1991).  
 
Knockout models in cells and animals and dominant negative mutant ANXA2 proteins have been 
developed in order to study the function of annexins (Gerke & Moss, 2002). Microscopy 
techniques such as cryoelectron microscopy and atomic force microscopy have been used to 
identify the formation of membrane domains and to study the interactions of different types of 
annexins with anionic phospholipids. Transmission and total internal reflection fluorescence 
microscopy (TIRF) have provided evidence that some annexins change conformation upon binding 
anionic phospholipids (Gerke & Moss, 2002). In considering the many different ways of studying 
annexins and the research equipment available, the Project Aim was developed.  
 
4.2 Project Aim 
This project was intended to characterize ANXA2 interactions with the anionic phospholipids PS 
and PI(4,5)P2, by studying whether altering calcium and anionic phospholipid concentrations 
promote or prevent ANXA2 self-association in vitro. The in vitro system used in these studies was 
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developed to shed light on the mechanism by which ANXA2 interacts with cellular membranes 
and anionic phospholipids in vivo to cause membrane rearrangement, producing lipid rafts which 
may serve as signaling platforms.  
This research was performed by analyzing the ability of the N-terminal domains of adjacent 
ANXA2 molecules to interact with other ANXA2 molecules in the presence and absence of PS 
and PI(4,5)P2.Purified ANXA2 protein was divided in half and fluorescently labeled. One half was 
labeled with a donor fluorophore (AlexaFluor 488 C5 Maleimide) and the other half was labeled 
with an acceptor fluorophore (AlexaFluor 568 C5 Maleimide). The fluorescent dye labeled the 
singular exposed cysteine residue on the N-terminal domain of ANXA2 (Fig. 4.2). After the 
protein was labeled, FRET experiments were performed in which lipid was titrated into a solution 
containing calcium chloride (0.5Mm) and varying concentrations of the acceptor and donor. After 
assessing the nature of this interaction, the importance of calcium in these experiments was 
elucidated by performing CaCl2 titrations into a solution containing 0.5mM EGTA, 0.5uM donor, 
and 2.0uM acceptor ANXA2.  The ability of ANXA2 to aggregate membranes was evaluated using 
dynamic light scattering (DLS). This research was intended to provide a platform for future 
ANXA2 characterization studies as well as to complement existing data regarding the interactions 
of ANXA2. Additionally, this research should expand current understanding regarding membrane 
domain formation by peripherally associated proteins. The FRET experiments may reveal useful 
information about changes in the quaternary structure of ANXA2 near its N-terminal cysteine 
residue upon lipid binding.  
 
Figure 4.2: Cysteine residues on ANXA2 ribbon diagram (Protein Workshop). 
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4.3 Literature Review of Related Experiments 
There have been a number of experiments performed by others which have elucidated the nature 
of the interactions between ANXA2 and anionic phospholipids. This subsection will discuss those 
experiments which are closely related to the Project Aim (4.2) and aided in the development of the 
Methodology (Chapter 5) as well as the Hypotheses and Project Goals (4.4). 
In 2013, Drucker et al. performed experiments with giant unilamellar vesicles (GUVs) in order to 
study the ability of ANXA2 to induce membrane domain formation. Upon binding GUVs 
containing PI(4,5)P2and cholesterol, ANXA2 (monomer and a mutant containing only the core 
domain) clustered the anionic lipids inducing lipid phase separation. Additionally, ANXA2 was 
shown to link adjacent GUVs and to induce membrane indentations in the presence of PI(4,5)P2, 
(Fig. 4.3). The membrane indentations produced by ANXA2 resulted in the inward vesiculation of 
the clustered lipids (also known as “membrane domains”). This phenomenon highlighted the 
potential role of ANXA2 in membrane trafficking. In these studies, the protein and calcium ion 
concentration were altered as well as the ratio of anionic lipids in the GUVs. These alterations 
indicated that increasing the concentration of anionic POPS (5-20% total lipid composition, 5ug) 
and CaCl2 (50-500uM) allows ANXA2 to bind more lipids as shown by an increase in the number 
of GUV-bound AlexaFluor® 568 fluorescence (Drücker et al., 2013). 
 
Figure 4.3: Lipid segregation and membrane budding induced by the peripheral membrane binding (Drücker et al., 2014). 
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The following year, Drucker et al. (2014) published a paper characterizing ANXA2 binding to 
solid-supported lipid bilayers (SLBs) containing varying concentrations of anionic phospholipids, 
such as PI(4,5)P2and POPS, using Quartz Crystal Microbalance (QCM). As a result of the 
piezoelectric effect, QCM measures mass variation per unit area or viscosity by calculating the 
resonance frequency of a sample using a quartz crystal oscillator. QCM is used to determine 
protein affinity on surfaces such as SLBs. These experiments were conducted in the presence and 
absence of cholesterol. This research indicated that ANXA2 cooperatively binds PI(4,5)P2to 
form  0.5–2 ± 0.2μm TopFluor PI(4,5)P2 domains that co-localize with labeled ANXA2. In the 
presence of cholesterol, the dissociation constant of monomeric ANXA2-lipid binding varied from 
22.1-32.2nM, depending on the lipid composition. These numbers indicate that binding is of high 
specificity and affinity (Drücker et al., 2014).  
The cause of the cooperativity which occurs when ANXA2 binds the plasma membrane in the 
presence of cholesterol, PI(4,5)P2, and POPS is unclear. The cooperativity of ANXA2 binding is 
believed to occur a result of one of the following phenomena (Drücker et al., 2014): 
ANXA2 Induces Lipid Reorganization: Bilayer reorganizations occur as a result of 
ANXA2 binding  
Lipids Stimulate Protein-Protein Interactions: Conformational change in AnxA2 results 
from lipid binding, enabling protein-protein contacts which facilitates further binding 
Lipid Reorganization Induces ANXA2 Binding: pre-existing domains of PI(4,5)P2 and 
cholesterol effect ANXA2 binding properties 
It is also possible that cooperativity results from a combination of these mechanisms. Lipid 
reorganization and protein-protein interactions could both be stimulated by lipid binding (Drücker 
et al., 2014).  
A study performed by Illien et al. (2012), characterized the role of calcium and pH in causing 
ANXA2 to aggregate membranes containing PI(4,5)P2 and POPS in the presence and absence of 
cholesterol. By looking at turbidimetry using a Cary spectrophotometer, Illien et al. (2012) studied 
the ability of ANXA2 to aggregate large unilamellar vesicles (LUVs) via membrane bridging at 
differing concentrations of calcium or hydronium ions. Under acidic conditions, ANXA2 has been 
shown to bind anionic phospholipids independent of calcium. A lipid/protein ratio of 25 was used. 
This research indicated that PS-containing membranes interact with ANXA2 to form membrane 
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bridges at a lower calcium concentrations than membranes comprised of PI(4,5)P2. The calcium 
concentrations required for half maximal membrane bridging (EC50) by monomeric ANXA2 
(5ug) was between 1.55uM and 91.2uM for POPS-containing membranes and between 3.31uM 
and 190.5uM for PI(4,5)P2-containing membranes. The calcium requirements for ANXA2 
interactions with PS-containing membranes is further lowered in the presence of cholesterol. The 
role of cholesterol in altering the calcium ion sensitivity of PI(4,5)P2–containing membranes is 
unclear. Unexpectedly, calcium ion sensitivity did not correlate with the concentration of anionic 
phospholipids involved in membrane binding. PI(4,5)P2is more negatively charged than POPS and 
should require more calcium ions to lower the electrostatic repulsion, enabling ANXA2 to form 
membrane bridges. Additionally, ANXA2 alters membrane fluidity upon lipid binding. PI(4,5)P2-
containing membranes lower membrane fluidity more than those containing POPS. This effect is 
most pronounced under acidic conditions than under high Ca2+ concentrations. Cholesterol further 
reduces membrane fluidity. These findings highlighted key differences between the ability of 
ANXA2 to aggregate membranes calcium dependently and calcium independently (Illien, Piao, 
Coué, Di Marco, & Ayala-Sanmartin, 2012). 
The role of the N-terminal domain in membrane bridging by ANXA2 was studied by Zibouche et 
al. (2008) using steady-state and time-resolved FRET of ANXA2 proteins fluorescently labeled at 
Cys-8 using acrylodan or N-(1-pyrene)maleimide and doxyl-labeled phospholipids (POPS/POPC) 
at different pH values. This study revealed a direct interaction between the N-terminal domain and 
the membrane. The distance of the labeled cysteine from the center of the bilayer (10.7 Å) was 
estimated from the quenching efficiency of 5-doxyl PC and 12-doxyl PC. Under mildly acidic 
conditions, N-terminal dimerization is not necessary for membrane bridging. An ANXA2 mutant 
lacking the N-terminal domain was capable of bridging membranes with a 2 to 3-fold lowered 
efficiency compared to the wild type suggesting that the N-terminal domain enhances the 
formation of membrane bridges under acidic conditions, but is not required for membrane binding 
(Zibouche et al., 2008).  
In addition to membrane binding, Zibouche et al. (2008) discovered interactions between the N-
terminal domains of adjacent ANXA2 proteins that were not in contact with the membrane as well 
as alterations in ANXA2 organization at the membrane as a result of changes in pH and Ca2+ 
concentration, suggesting that ANXA2 changes conformation under differing reaction conditions 
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which could help to explain its diverse role within the human body. By performing fluorimetry 
experiments Zibouche et al. found that vesicle aggregation was stronger under acidic conditions 
than under high Ca2+ conditions (pH 7). This finding led them to perform cryo-electron microscopy 
where they saw that under mildly acidic conditions ANXA2 appears to organize in a single protein 
layer while in the presence of Ca2+ (pH 7), two layers of ANXA2 protein form. The presence of 
two layers indicates face-to-face dimerization of ANXA2 molecules. The presence of differing 
protein arrangements was further supported by calculating that the amount ANXA2 required for 
half-maximal membrane aggregation under high Ca2+ conditions (3.1mM, pH 7) was 
approximately double (5.1 ± 0.2 μgml-1) the amount of ANXA2 required under acidic conditions 
(2.5 ± 0.2 μg ml-1, pH 4). The degree of cooperativity was also found to be one molecules greater 
in the presence of Ca2+ (Hill number 0.90) than under acidic conditions (Hill number 0.34). 
Collectively, this data suggests that changes in the physiological conditions of a cell dictate the 
arrangement of ANXA2 molecules. By studying the nature of the conformational changes and 
organization of ANXA2 much can be learned about its functional role in various bodily functions 
(Zibouche et al., 2008). 
The ability of ANXA2 to self-associate is controversial. There is still much that needs to be learned 
about how and why this occurs. In 1991, Zaks and Creutz studied annexin association using 90° 
light scattering and resonance energy transfer with an eosin–labeled acceptor annexin protein and 
a fluorescein–labeled donor annexin protein. Annexin IV, annexin VI, and annexin VII were 
studied. In solution, all of the annexins exhibited self-association in a calcium-dependent fashion 
that varied in reproducibility and consistency. When these proteins were bound to chromaffin 
granules (neuroendocrine cells found in the adrenal glands), self-association was more consistent 
and reproducible. Calcium levels of 10.0uM-31.6uM (pCa5.0-4.5) were studied. POPS and POPE-
containing vesicles self-associated poorly compared to POPS and POPC-containing vesicles. At 
calcium concentrations less than 100uM (pCa 4), annexins VII and IV self-associated when bound 
to chromaffin granules while at higher calcium concentrations (more than pCa 4, 100uM), there 
was no self-association. Therefore at higher calcium concentrations it appears that ANX IV, VI, 
and VII binds membranes as a monomer, which is the exact opposite of Zibouche et al.(2008)’s 
findings, which suggests that ANXA2 binds membranes as a monomer at high calcium 
concentrations (Zaks & Creutz, 1991), which may be due to differences in the size of the N-
terminal domain of each type of annexin protein.  
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In 2005, Patel et al. further found that annexin A5 and B12 associate strongly in the presence of 
anionic phospholipids (0.1mM) and calcium (0.5mM) but annexin A1 and A2 do not. These studies 
used 4nM ANXA2 labeled with acceptor dye (AlexaFluor 532 C5 Maleimide), 10nM ANXA2 
labeled with donor dye (AlexaFluor 647 C5 Maleimide), anionic phospholipid vesicles (2:1 PS: 
PC), and HEPES buffer (20mM HEPES, pH 7.4). In some experiments, they observed small 
change in the acceptor of ANXA2 upon membrane binding likely due to chance interactions of a 
donor and acceptor bound to the same vesicle. The probability of these chance interactions 
occurring could be amplified by raising the concentration of ANXA2 in the interaction. Further 
research needs to be performed to further validate these findings as well as to uncover how the 
differing lengths and amino acid sequences of the N-terminal domain can interact with anionic 
phospholipids in vastly different manners (Patel et al., 2005). 
 
4.4 Hypotheses and Goals 
1. To determine if ANXA2 self-associates in the presence and absence of lipid vesicles 
containing PI(4,5)P2, PS, and PC. 
This goal was designed to see if the addition of PI(4,5)P2will promote the self-association of 
ANXA2 upon lipid binding, as shown in Figure 4.4. I hypothesize that PI(4,5)P2will promote self-
association upon membrane binding. As shown by Drucker et al. (2013), PI(4,5)P2 induces 
membrane indentations leading to the inward vesiculation of membrane domains, which could be 
assisted by the self-association of the N-terminal domains of adjacent ANXA2 molecules. It has 
previously been shown that ANXA2 should not self-associate when free in solution or in the 
absence of Ca2+ at neutral pH. Patel et al. (2005) found that the N-terminal domains of ANXA2 
and ANXA1 self-associate poorly in response to vesicles containing POPS and POPC, but small 
amounts of interaction were detectable by FRET. These studies will be carried out by performing 
FRET experiments in a similar fashion to the experiments performed by Patel et al. (2005). As a 
result of these experiments it will be possible to further characterize how ANXA2 interacts with 
anionic phospholipids on membranes by determining the role of PI(4,5)P2in membrane trafficking 
by evaluating the self-association of ANXA2 in the presence of PI(4,5)P2.  
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2. To determine if altering the calcium concentration affects self-association. 
In order to determine if ANXA2 self-association is promoted at high or low concentrations of Ca2+ 
(CaCl2) Ca
2+ titrations were performed at pH 7.4 into a solution containing 0.5uM acceptor, 2uM 
donor, and 0.5mM EGTA. I hypothesize that at high Ca2+ concentrations the rate of self-
association will decrease. These experiments should indicate the role of self-association of 
ANXA2 upon membrane binding and the role of ANXA2 in the formation of membrane domains. 
This information could be used to predict the effects of increases or decreases in Ca2+ concentration 
in vivo, which could be helpful in assessing the role and mechanism of calcium signaling regulation 
in the interactions of ANXA2. 
  
Figure 4.4: Predicted manners in which the N-terminally labeled cysteine residues of ANXA2 A488 and ANXA2 A568 can self-associate in the 
presence of anionic lipids 
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3. To determine whether altering the concentrations and composition of anionic 
phospholipids affects the interaction of the N-terminal domains of ANXA2. 
This goal has two purposes. The first is to assess the effects of light scattering by lipid vesicles to 
determine whether or not the Ca2+ was causing the lipids to aggregate in such a way that it inhibited 
ANXA2 interactions with the membrane. This will be done by using differing ratios of PC and 
PS/PI(4,5)P2 which will have the same reaction conditions and volume. PC is a neutral phospholipid 
which does not bind ANXA2. Therefore, I hypothesize that there should be no FRET transfer with 
100% PC vesicles and any decreases in donor excitation will be due to light scattering by lipids. 
This will serve as a control for assessing the validity of ANXA2 interactions. 
 
The second purpose was due to findings by Patel et al. (2005) which suggested that high 
concentrations of ANXA2 can cause chance association of the N-terminal domain of two ANXA2 
molecules. Therefore, it was necessary to use both low, medium, and high concentrations of lipids 
to interpret whether self-association was a chance occurrence or a reproducible phenomenon.  
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CHAPTER 5—METHODOLOGY 
Chapter 5: Methodology begins by discussing ANXA2 WT plasmid preparation (Section 5.1). 
Section 5.2 describes the protein expression protocol. Section 5.3 outlines the steps necessary for 
ANXA2 WT purification. Section 5.4 describes how the protein was quantified, how the purity 
was assessed, and how the protein was stored. Section 5.5 explains how ANXA2 WT was 
concentrated and fluorescently labeled. Section 5.6 outlines how the FRET experiments were 
performed.  
5.1 Plasmid Preparation 
The ANXA2 WT DNA used in these experiments was inserted into a pSE420 vector, the vector 
map can be found in Appendix B (8.2). The DNA sequence of ANXA2 WT used in these 
experiments is PDB ID 1XJL. The DNA and protein sequence for ANXA2 WT can be found in 
Appendix C (8.3).  In order to amplify the DNA for expression, 117 ng of ANXA2 WT DNA was 
transformed into TOP10F’ super competent cells. The cells were regenerated by adding 350uL of 
SOB recovery media and the transformant was incubated at 37°C for 1hr on a rotator. 20uL of 
transformant was plated onto an LB-AMP plate (150mg/mL ampicillin). The plate was left 
overnight in a 37°C incubator. A single colony was inoculated into 4mL of LB broth containing 
150mg/mL ampicillin and placed in the shaker (270rpm, 37°C) overnight. The culture was 
centrifuged at 11,000xg for 3 minutes using an accuSpinTM 1R swing bucket rotor. The pellet was 
suspended in 600uL of autoclaved water. A Zippy maxi-prep plasmid purification kit was used to 
isolate and purify the plasmid DNA. The DNA concentration was measured using a Nanodrop and 
sent out for sequencing. The forward primers designed for sequencing was 
5’GCTGGGAACCGACGAGGACT3’ and the reverse primer was 5’TAGACTCTG 
TTAATTTCCTGCAGCTC 3.’ The sequence alignment can be found in Appendix C (8.3).  
5.2 Protein Expression 
In order to express the protein, 237ng purified ANXA2WT plasmid DNA was transformed into 
BL21 super competent cells. The cells were regenerated by adding 350uL of SOB recovery media 
and the transformant was incubated at 37°C for 1hr on a rotator. The transformant was pipetted 
into a 100mL LB starter culture containing 150mg/mL ampicillin and was grown overnight in a 
shaker (250rpm, 37°C). The entire starter culture was added to a flask containing 900mL LB, 
150mg/mL ampicillin and 200uL of antifoaming agent. The flask was placed into the shaker 
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(250rpm, 37°C) and incubated until it reached an OD of 0.7. At an OD of 0.7 the culture was 
induced with 1mM IPTG, incubated in the shaker for 3 hours (250rpm, 37°C), and chilled in the 
cold room for 30 minutes. The cell culture was centrifuged at 5,000xg for 10 minutes at 4°C. The 
supernatant was discarded and the pellets were resuspended in lysis buffer (50mM imidazole, 
300mM NaCl, 10mM MgCl2, 2mM DTT, 1 capsule Complete Protease Inhibitor EDTA-free, pH 
7.4, 3 mL/g of wet pellet), and stored in -80°C.  
5.3 Protein Purification 
5.3.1 French Press 
The ANXAT WT cell pellets (-80°C) were thawed in a hot water bath (37°C) and lysis buffer was 
added to a total volume of 40mL and placed on ice. The mixture was passed through the French 
press three times at 1,000 psi and then centrifuged at 30,000rpm in a Beckman Coulter 
Ultracentrifuge (1hr, 4°C). The supernatant was dialyzed overnight in the cold room in 3L of DE 
buffer (10mM imidazole, 10mM NaCl, 1mM EGTA, 2mM DTT, pH 7.4) at 4°C using 
10,000MWCO SnakeSkin® Dialysis Tubing (3.7mL/cm). The DE buffer was replaced with an 
additional 3L of DE buffer and dialyzed for 2-3 hours. 
5.3.2 DE Column 
The GE Healthcare DEAE Sephacel column material (5mL in 4, 50mL conical tubes, 20mL total) 
was hydrated by adding 40mL of DE buffer and rocking at 4°C for 15 minutes. The tubes were 
centrifuged in an accuSpinTM1R swing bucket rotor at 1,500xg for 2 minutes and the buffer was 
removed and 40mL of DE buffer was added. These steps were repeated three times and then the 
ANXA2WT protein was transferred from the dialysis tubing and aliquoted into the hydrated DE 
column material. The ANXA2 WT protein was incubated with the DE column material on the 
rocker in the cold room for 2 hours. The protein and column material was added to a column and 
left to settle for 30 minutes. The flow through was collected and then 40mL of DE buffer was 
passed through and collected (“wash” fraction). The flow through and wash fractions were 
centrifuged in the Beckman Coulter Ultracentrifuge at 30,000 rpm for1 hour at 4°C. The 
supernatant of the wash and flow through were placed into separate 10,000MWCO SnakeSkin® 
Dialysis Tubing (3.7mL/cm) and were dialyzed in the cold room overnight in 3L of CM buffer 
(20mM sodium acetate, 10mM NaCl, 1mM EGTA, 2mM DTT, pH 5.6). The buffer was replaced 
with an additional 3L of CM buffer once and allowed to dialyze for 2-3 hours. 
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5.3.3 CM Column 
The Sigma Carboxymethyl Sepharose® (CM) column material (2.5mL in 6, 50mL conical tubes, 
15mL total) was hydrated by adding 42.5mL of CM buffer and rocking at 4°C for 15 minutes. The 
tubes were centrifuged in an accuSpinTM1R swing bucket rotor at 1500xg for 2 minutes and the 
buffer was removed and 42.5mL of CM buffer was added. These steps were repeated three times 
and then the ANXA2 WT wash and flow through fractions were transferred from the dialysis 
tubing and aliquoted into the hydrated CM column material (5mL column material for the wash 
and 10mL column material for the flow through). The ANXA2 WT protein was incubated with 
the CM column material on the rocker in the cold room for 2 hours. Two columns were set up, 
CM buffer was passed and the columns were stoppered. The flow through and column material 
was added to one column and the wash and column material to another. The columns were allowed 
to settle for 30 minutes. The flow through in each column was drained and 15mL of CM buffer 
was passed through each column twice. Then, 15mL of CM buffer containing an additional 
100mM NaCl was passed three times through the column. The ANXA2 WT protein was eluted by 
passing 10mL of CM buffer containing an additional 600mM NaCl three times. Each 10mL 
fraction was collected separately. 
5.4 Purity Assessment, Quantification of Protein Concentration, and Storage 
A 15% denaturing SDS-PAGE gel was run with 20uL of sample and 5uL of 5x SDS running 
buffer. The gels were stained with Fairbanks staining (25% isopropanol, 10% acetic acid, 0.05% 
Coomassie R) and destained with a 10% acetic acid solution. The gel bands were sent out and 
assessed by mass spectrometry, as shown in Appendix D (8.4). Additionally, a Western Blot was 
performed. A 15% SDS-PAGE gel was ran with 20uL of sample and 5uL of 5x SDS running buffer 
and transferred onto a Thermo-Scientific Nitrocellulose Membrane (0.45micron, prod#88018) at 
150mA for 1.5 hours. After washing the membrane in Millipore water, the membrane was 
incubated with the primary antibody, Cell Signaling Technology Annexin A2 (D11G2) Rabbit 
mAb (#8235), overnight on a rocker at 4°C.  The primary antibody (10uL) was prepared in a 1X 
TBS (pH 7.4) solution containing 5% milk fat (10mL).  The membrane was washed, by adding 1x 
TBS-Tween (pH 7.4) buffer to the membrane and rocking for 15 minutes at room temperature 
(3x). The secondary antibody was incubated with the membrane on the rocker at room temperature 
for 1 hour. The secondary antibody, Cell Signaling Technology Anti-rabbit goat IgG, was prepared 
in a 1x TBS-Tween solution containing 1% milk fat (10mL).  The membrane was washed, by 
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adding 1x TBS-Tween buffer to the membrane and rocking for 15 minutes at room temperature 
(3x). The membrane was then washed in water. ClarityTM Western ECL Substrate (1mL, 
prod#170-5061) was added to the membrane and the membrane was scanned using a Bio-Rad 
Chemi-Doc XRS+. 
A Malvern Instruments DLS (Dynamic Light Scattering) was used with Zetasizer® software to 
monitor protein aggregation. The samples were scanned using a low volume (50uL) quartz cuvette 
with a 3.00mm path length. A measurement angle of 173° was used.  
For storage purposes, the protein was dialyzed into MES buffer (20mM MES, 150mM NaCl, 2mM 
DTT, 1mM NaN3, pH 6.0) using 3-12mL 10,000MWCO Slide-A-Lyzer® dialysis cassettes 
(Prod#66810). The dialyzed protein was stored on ice in the cold room (4°C). For experiments, 
the ANXA2 WT protein was dialyzed into HEPES buffer (20mM HEPES, 150mM NaCl, pH 7.4). 
The protein was concentrated to approximately 1mg/mL using 5mL Amicon® Ultra Centrifugal 
Filters, Ultracel®-10K. The filters were hydrated by adding 5mL of HEPES buffer and spinning 
the filters for 9 minutes at 2,000rcf in an accuSpinTM 1R swing bucket rotor. Then, 5mL of ANXA2 
WT (5mL) was added to the filters and the protein was concentrated to 1mL in the accuSpinTM 1R 
swing bucket rotor at 2,500rcf for approximately 6 minutes. The protein concentration of the wash 
and flow through elution fractions was assessed using a NanoDrop at an absorbance of A280. The 
extinction coefficient (30,250 M-1 cm-1) and the molecular weight (38,485Da) were used to 
calculate the protein concentration. Three samples of each protein were taken and the average 
value was used.  
5.5 Fluorescent Labeling 
Concentrated ANXA2 WT protein in HEPES buffer was separated into two 500mL fractions. Half 
of the protein was labeled overnight (4°C) with a 10x molar excess of AlexaFluor488 C5 
Maleimide Dye and the other half was labeled overnight in a 10x molar excess of AlexaFluor568 
C5 Maleimide Dye. The dye was quenched with a 10x molar excess of Sigma Aldrich® beta-
mercaptoethanol for 20 minutes. Unlabeled dye was removed by dialyzing the protein in 100mL 
of HEPES buffer using 0.1-0.5 10,000MWCO Slide-A-Lyzer® dialysis cassettes (Prod#66383). 
The buffer was changed every 30 minutes for 4 hours. The degree of labeling and the protein 
concentration was assessed using the NanoDrop. The extinction coefficient (30,250 M-1 cm-1) and 
the molecular weight (38,485Da) were used to calculate the protein concentration. Three samples 
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of each protein were taken and the average protein concentration was used. The samples were 
stored on ice at 4°C. 
5.6 FRET 
5.6.1 Spectrometer Settings 
A F-4500 FL Fluorescence Spectrometer was used for these experiments. The excitation 
wavelength was set to 493nm. The emission wavelength was scanned from 500nm-750nm. The 
scan speed was 60nm/min and the PMT voltage was 950V. The response time used was 8sec, the 
cycle time was 5 minutes, and the delay time was 0 sec. The excitation and emission slits were 
2.5nm and the reaction temperature was 20°C.  
5.6.2 Sample Preparation 
The samples were prepared in a low volume (50uL) quartz cuvette with a 3.00mm path length. 
The total sample volume was 60uL. Before each experiment the fluorescently labeled ANXA2 
WT was scanned in the DLS to monitor protein aggregation. All experiments were performed in 
HEPES buffer. 
5.6.2.1 Lipid Titrations 
For all experiments, a starting concentration of 0.5mM CaCl2 was used. The acceptor to donor 
concentration (0.5uM) was 4 to 1, 3 to 1, or 2 to 1. The lipid vesicles (0.3mM) were titrated in 
increments of either 2uL or 3uL.  
5.6.2.2 Calcium Chloride Titrations 
Starting concentrations of 0.5uM EGTA, 0.5uM donor, 2uM acceptor, and 75uM lipid were used.  
10uM CaCl2 solution was titrated in increments of either 2uL or 3uL. 
5.6.3 Lipid Preparation 
Lipid samples were prepared according to the Avanti website3 and lipid concentration was verified 
by performing phosphate assays. The desired lipid composition and concentration was measured 
and the lipids were dried using a stream of nitrogen while gently heating the lipids on a hot plate. 
The lipid films were stored in a vacuum overnight, then resuspended in the experimental buffer 
(HEPES), vortexed, and extruded through a 100nm polycarbonate filter using an extrusion kit. 
                                                          
3 https://avantilipids.com/ 
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Lipid vesicle size distribution was verified using A Malvern Instruments DLS (Dynamic Light 
Scattering) with Zetasizer® software. The samples were scanned using a low volume (50uL) 
quartz cuvette with a 3.00mm path length at a temperature of 20ºC. The measurement angle was 
173°, the count rate was 339.9kcps, and the measurement position was 4.20mm.  
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CHAPTER 6—RESULTS AND DISCUSSION 
This chapter will begin by discussing the results of the ANXA2 purification (6.1). Then the 
following sections will discuss the results of the FRET titration experiments in order of the varying 
lipid compositions: 95% POPC 5% PI(4,5)P2 (6.2), 65% POPC 5% PI(4,5)P230% POPS (6.3), 55% 
POPC 15% PI(4,5)P230% POPS (6.4), and 85% POPC 15% PI(4,5)P2. 
6.1 ANXA2 Purification and Quality Assessment 
In order to study the interaction of the N-terminal domains of adjacent ANXA2 proteins, the 
ANXA2 wild type protein was expressed in BL21 bacterial cells which produced cell pellets of 
approximately 2.5g per 1L of culture. Approximately 7.5g of ANXA2 cell pellet were lysed and 
purified in order to eliminate cellular debris which could inhibit the specific activity of ANXA2. 
Purifying ANXA2 also improves the collisional efficiency of fluorescent labeling of the singular 
exposed cysteine residues on the N-terminal domain of ANXA2, leading to a better degree of 
labeling. Additionally, if ANXA2 were labeled immediately after lysis, the fluorescent signal in 
the FRET assays would be strongly diminished. ANXA2 purification resulted in a large band at 
approximately 32KDa, with greater than 95 % purity as shown by the denatured SDS-PAGE gel 
in Fig.6.1A. This band was lower than expected, accordingly a Western blot was performed, as 
shown in Fig. 6.1B, to ensure that the bands were ANXA2. The Western blot verified that the 
bands on the SDS-PAGE gel were ANXA2, which was further verified using mass spectroscopy 
as shown in Appendix D (8.1). Mass spectrometry was performed to verify that the small band 
beneath the ANXA2 band in the SDS-PAGE gel was not a protein which could have cysteine 
residues which could be labeled by the AlexaFluor dye. The band was found to be a small amount 
of E.coli contamination which would not affect the fluorescence experiments. 
 
Figure 6.1: (A) Denatured SDS-PAGE Gel of ANXA2 Purification. Left to Right:  6 HEPES Buffer, CM Fraction 6 MES Buffer, CM 
Fraction 7 HEPES Buffer, CM Fraction 7 MES Buffer. (B) Western Blot after ANXA Purification. Left to Right: (1) French Press Flow 
through, (2) French Press pellet, (3) DE Flow Through,(4) CM Flow Through Fraction 6, (5) CM Wash Fraction 6. 
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After ensuring that the ANXA2 was pure, the protein was concentrated to approximately 
1.3mg/mL to improve the collisional efficiency of the ANXA2 protein with either the AlexaFluor 
C5 488 Maleimide dye or the AlexaFluor C5 568 Maleimide dye. The optimal protein 
concentration for protein labeling with this dye is 2mg/mL, but the ANXA2 protein has a 
propensity to aggregate at higher concentrations, therefore a lower protein concentration was 
favored to maintain the stability of the protein. The concentrated ANXA2 protein was then 
dialyzed against 20mM HEPES, 150mM NaCl, pH 7.4 buffer to remove the MES storage buffer 
which contains DTT and sodium azide which interfere with FRET experiments. After 
concentrating and dialyzing, the protein was labeled and the unreacted dye was deactivated and 
removed through dialysis. The degree of labeling was found to be 1.2 for the AlexaFluor C5 488 
Maleimide-labeled ANXA2 and 0.44 for the AlexaFluor C5 568 Maleimide-labeled ANXA2. This 
degree of labeling was sufficient for experimentation. 
Prior to experimentation, the ANXA2 A488 and the ANXA2 A568 proteins were assessed for 
aggregation using the Dynamic Light Scattering (DLS) Zetasizer software. According to the 
Malvern website, this software measures the size of a sample by measuring particle diffusion 
according to Brownian motion and converts this to a size distribution using the Stokes-Einstein 
relationship. The size of the ANXA2 A488 was approximately 5.7 nm and the size of the ANXA2 
A568 was approximately 4.6nm, which indicated that the proteins were not aggregated as shown 
in Fig. 6.2 and Fig.6.3, respectively. 
 
Figure 6.2: DLS Size Distribution by Volume of ANXA2 Fluorescently Labeled with the Donor AlexaFluor488 Prior to 
Experimentation. All of the donor ANXA2 used in these experiments had a singular peak with a size of approximately 5.7nm. 
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Figure 6.3: DLS Size Distribution by Volume of ANXA2 Fluorescently Labeled with the Acceptor AlexaFluor568 Prior to 
Experimentation. All of the acceptor ANXA2 used in these experiments had a singular peak with a size of approximately 4.6nm.  
The lipid vesicles used in these experiments were all size-verified using the DLS Zetasizer 
software in order to ensure that the extrusion kit produced vesicles of approximately 100nm. The 
lipid vesicles used in all experiments has a Z-average (d.nm) of 100±17 and were of good quality 
as shown in Fig. 6.4. 
 
Figure 6.4: DLS Size Distribution by Volume of Lipid Vesicles after Extrusion. All of the lipid vesicles used in these experiments had 
a Z-Average (d.nm) of approximately 100 ± 17 and were of good quality according to the DLS Zetasizer software. 
6.2 FRET Experiments with 95% POPC, 5% PI(4,5)P2 Lipid Composition 
In order to determine the role of PI(4,5)P2 in stimulating the association of the N-terminal domains 
of ANXA2, 95% POPC, 5% PI(4,5)P2was used in order to mimic the physiological ratio of 
PI(4,5)P2present at the inner leaflet of the plasma membrane. Varying ratios of ANXA2 acceptor 
(ANXA2 A5568) to donor (ANXA2 A488) were used to identify the optimal ratio for FRET 
interaction. Preliminary experiments were performed with 2 to 1 acceptor to donor concentrations 
using 100% POPC lipids and 70% POPC, 30% POPS lipids, but the acceptor band emitted poorly 
at 493nm excitation, therefore higher ratios were tried in these experiments (Appendix E, Section 
8.5). 
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A donor alone experiment was performed as a control to ensure that the changes in donor 
fluorescence was due to FRET transfer and not a byproduct of light scattering by lipids, direct 
excitation or other aspects of the experimental setup. The donor alone titration had an average 
donor emission fluorescence intensity which was 90.5% of the fluorescence intensity of the donor 
emission at 493nm excitation prior to lipid addition; an overall 9.5% decrease in fluorescence 
intensity.  Table 1 in Appendix F shows that in the Trial 1 donor alone experiment the average 
change in the fluorescence intensity of the donor emission was 89.5% (10.5% decrease), Trial 2 
had an average change of 87.2% (12.8% decrease), and Trial 3 had an average change of 93.6% 
(6.4% decrease).  
A graph of the dilution corrected emission spectra after each lipid addition for each trial as well as 
a graph in the changes in fluorescence intensity upon lipid addition can be found in Fig. 6.5. 
Increasing the lipid to protein ratio which can be found in Table 17 in Appendix G, did not lead to 
a steady decrease in the donor fluorescence which could have numerous causes. The fluctuation in 
fluorescence intensity may have resulted from the degree of mixing of the solution, which would 
alter whether or not aggregated proteins were at the bottom of the cuvette when the fluorescence 
emission was scanned.  
 
Figure 6.5: 95% POPC 5% PI(4,5)P2 Donor Alone Lipid Titration. Starting concentration: 0.5uM donor AlexaFluor 488 ANXA2 and 
0.5mM CaCl2. The emission spectra were dilution corrected to better display changes in fluorescence intensity upon lipid addition. 
See Table 17 Appendix G for a summary of the different ratios of lipid to protein and the calcium concentration differences upon 
lipid addition. (A) T1- Change in Fluorescence intensity of the Emission Spectra Upon Lipid Addition (B) T2- Change in Fluorescence 
intensity of the Emission Spectra Upon Lipid Addition (C) T3- Change in Fluorescence intensity of the Emission Spectra Upon Lipid 
Addition (D)Change in Ratio of Fluorescence Intensity Upon Lipid Addition, all values for each trial were divided by the fluorescence 
intensity when there were no lipids present. 
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The 3 to 1 ratio of acceptor to donor (2.0uM, 0.5uM), showed similar results to the donor alone 
graph with more variation in the change in the donor and acceptor emission at an excitation of 
493nm. The average donor emission fluorescence intensity of the 3 to 1 acceptor donor was 92.5% 
of the fluorescence intensity of the donor emission at 493nm excitation prior to lipid addition; an 
overall 7.5% decrease in fluorescence intensity; which is a slightly smaller decrease in the donor 
emission fluorescence intensity compared to the donor alone average decrease of 9.5% indicating 
that no FRET transfer occurred. Table 2 in Appendix F shows that in the Trial 1 the average change 
in the fluorescence intensity of the donor emission was 97.6% (2.4% decrease) and Trial 2 had an 
average change of 92.8% (7.2% decrease). The 3 to 1 experiment likely had a smaller decrease in 
the fluorescence intensity of the donor emission because there was a smaller lipid to protein ratio 
(Table 18 Appendix G) because there was more ANXA2 present in the system.  
The change in acceptor emission upon lipid addition were also recorded in Table 2 Appendix F to 
show if the changes in fluorescence intensity were a result of the conditions of the experiment or 
whether actual FRET transfer was occurring. As evidenced by the graph of the change in 
fluorescence intensity upon lipid addition in Fig. 6.6, it appears that the acceptor and donor 
emissions for each trial follow similar patterns of increases and decreases upon lipid addition. If 
FRET transfer were occurring the acceptor emission should increase while the donor emission 
decreases. These changes are likely a result of variations in mixing which alters which labeled 
ANXA2 proteins are aggregated at the bottom of the solution and which ANXA2 protein’s signals 
are being clouded by the lipids.  
Interestingly, it appears that the ANXA2 A568 acceptor protein slightly increased in fluorescence 
intensity, with the average ratio of the change of the acceptor emission being 104% (4% increase) 
in both trials, as shown in Table 2 Appendix F, indicating that lipid scattering effects lowers the 
donor emission while increasing the acceptor emission. An acceptor alone trial will need to be 
performed in the future in order to further verify this difference.  
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Figure 6.6: 95% POPC 5% PI(4,5)P2 3 to 1 Acceptor to Donor Lipid Titration. Starting concentration:  0.5uM donor AlexaFluor 488 
ANXA2, 1.5uM acceptor AlexaFluor 568 ANXA2, and 0.5mM CaCl2. The emission spectra were dilution corrected to better display 
changes in fluorescence intensity upon lipid addition. See Table 18 Appendix G for a summary of the different ratios of lipid to 
protein and the calcium concentration differences upon lipid addition. (A) T1- Change in Fluorescence intensity of the Emission 
Spectra Upon Lipid Addition (B) T2- Change in Fluorescence intensity of the Emission Spectra Upon Lipid Addition (C) Change in 
Ratio of Fluorescence Intensity Upon Lipid Addition, all values for each trial were divided by the fluorescence intensity when there 
were no lipids present. 
The ratio of acceptor to donor ANXA2 was further raised to 4 to 1 (2.0uM, 0.5uM), as shown in 
Table 19 Appendix G, in order to further diminish the lipid to protein ratio to see if this would 
raise the chance that the ANXA2 A488 and ANXA2 A568 would interact with each other when 
there are no accessible anionic lipid binding sites for it to bind to. In this system, the fluorescence 
intensity of the donor emission was lower than the 3 to 1 acceptor to donor experiments and the 
donor alone experiments, as shown in Fig. 6.7. The average change in donor emission fluorescence 
intensity was 71.2% of the starting fluorescence intensity, with the donor emission fluorescence 
intensity decreasing 39% immediately upon adding 14.29uM 95% POPC 5% PI(4,5)P2 to the 
solution (Table 3, Appendix F). This difference suggested that a FRET transfer may have occurred, 
but the acceptor ANXA2 A568 emission fluorescence intensity only increases approximately 8%, 
as shown in Table 3 Appendix F, which is not consistent with a 39% decrease in the donor 
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intensity. Inconsistencies in FRET transfer may be due to the nature of the spectral overlap, thus a 
different donor/acceptor pair with a larger Forster distance should be used in the future.  
There is little change in the fluorescence intensity after the first lipid addition, which suggests that 
by chance, there may have been a lot of PI(4,5)P2 in the first lipid addition and not in the subsequent 
additions. If there was enough PI(4,5)P2it is possible that all of the donor ANXA2 A88 was bound 
to the membrane in such a manner that they could no longer interact with the acceptor ANXA2 
A568. In the future, more trials of the 4 to 1 acceptor to donor 95% POPC 5% PI(4,5)P2 should be 
performed to see if these findings are consistent. 
 
Figure 6.7: 95% POPC 5% PI(4,5)P2 4 to 1 Acceptor to Donor Lipid Titration. Starting concentration:  0.5uM donor AlexaFluor 488 
ANXA2, 2.0uM acceptor AlexaFluor 568 ANXA2, and 0.5mM CaCl2. The emission spectra were dilution corrected to better display 
changes in fluorescence intensity upon lipid addition. See Table 19 Appendix G for a summary of the different ratios of lipid to 
protein and the calcium concentration differences upon lipid addition. (A) T1- Change in Fluorescence intensity of the Emission 
Spectra Upon Lipid Addition (B) Change in Ratio of Fluorescence Intensity Upon Lipid Addition, all values for each trial were divided 
by the fluorescence intensity when there were no lipids present. 
At the end of each of the 95% POPC 5% PI(4,5)P2FRET titrations experiments, the DLS Zetasizer 
was used to monitor aggregation in the solution. There was minimal lipid aggregation which could 
alter the FRET signal by affecting lipid scattering as indicated by using the DLS Zetasizer data in 
Fig. 6.8. There were two peaks, one at approximately 130nm which comprises 88.3% of the 
samples and the other at approximately 4800nm which is 11.7% of the solution. The 130nm peak 
was likely the lipid peak and the 4800nm peak was likely the aggregated lipid and ANXA2 protein. 
This indicated that although high concentrations of calcium chloride (0.384mM-0.5mM, factoring 
in the dilution caused by lipid addition) were used in these experiments, which can cause 
PI(4,5)P2containing vesicles to aggregate by altering electrostatic interactions (Ellenbroek et al., 
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2011) and can facilitate ANXA2-mediated aggregation of membrane containing anionic 
phospholipids (Gerke & Moss, 2002), the concentrations of PI(4,5)P2 was low enough that it did not 
overly cloud the system.  
 
Figure 6.8: DLS Size Distribution by Volume of the ANXA2 Labeled with AlexaFluor 488 and ANXA2 Labeled with AlexaFluor 568 
after titration with 95% POPC 5% PI(4,5)P2. 
6.3 FRET Experiments with 65% POPC, 5% PI(4,5)P2, 30% POPS Lipid Composition 
After performing the 95% POPC 5% PI(4,5)P2FRET assays, POPS was added to the vesicles to see 
if this would effect ANXA2 self-association at the N-terminal domain. Previously, Patel et al. 
(2005), indicated that the N-terminal domain of ANXA1 and ANXA2 cannot self-associate in the 
presence of POPS unless their core domains are swapped with annexin proteins with a known 
propensity to self-associate, such as ANXA5 and ANXB12. Even so, Patel et al. (2005) 
occasionally detected small amounts of FRET transfer with wild type ANXA2. For the 4 to 1 
acceptor to donor ANXA2 ratio and  95% POPC, 5% PI(4,5)P2vesicles, only small amounts of 
possible FRET transfer was observed. Both systems suggested a similarly low propensity for self-
association, but adding POPS to the PI(4,5)P2system may cooperatively assist self-association by 
improving membrane binding by ANXA2. In 2013, Drucker et al. found that ANXA2 binds 
cooperatively to membranes containing PI(4,5)P2, POPS, and cholesterol using a quartz crystal 
microbalance (QCM). 
In order to determine this, a 4 to 1 acceptor to donor FRET lipid titration experiment was performed 
using 65% POPC, 5% PI(4,5)P2, and 30% POPS. The physiological mol concentration of POPS in 
the inner leaflet of the plasma membrane is approximately 30%. Donor alone control titrations was 
performed to determine the baseline change in fluorescence transfer due to lipid scattering and 
other factors which could alter the fluorescence intensity of the donor emission. The donor alone 
experiments highlighted an average decrease in fluorescence intensity of the donor emission 
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compared to the donor emission before lipid addition of 6.4% (fluorescence intensity which is 
93.6% of the fluorescence intensity without lipid). The changes in fluorescence intensity upon 
lipid addition is graphed in Fig. 6.9 and the actual numerical values can be found in Table 4 and 
5, Appendix F. In the 4 to 1 acceptor to donor trials, the alterations in donor and acceptor emissions 
varied per trial and there was no significant alteration in fluorescence intensity which would 
suggests that FRET transfer occurred.  
By evaluating the change in the acceptor emission in the donor alone graph, upon lipid addition 
when no acceptor was present, it was possible to see the natural fluctuations in the acceptor peak, 
as shown in Table 5, Appendix F. This evaluation made it appear that the reduction in the donor 
emission fluorescence intensity upon lipid addition was not due to FRET transfer. The clearest 
indication that FRET transfer did not occur was indicated by Fig. 6.9E which divides the 4 to 1 
acceptor to donor fluorescence intensities of the donor emission by the donor alone emission which 
produced relatively flat lines around 1.0, indicating that the values of each are roughly the same. 
A more detailed evaluation showing how lipid addition altered the lipid to protein ratio, the calcium 
concentration, and the concentrations of acceptor ANXA2 A568 and ANXA2 A488 can be found 
in Tables 20-21, Appendix G. 
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Figure 6.9: 65% POPC 5% PI(4,5)P2 30% POPS 4 to 1 Acceptor to Donor Lipid Titration.  Starting concentration: 0.5uM donor 
AlexaFluor 488 ANXA2, 2.0uM acceptor AlexaFluor 568 ANXA2, 0.5mM starting calcium chloride concentration.  The emission 
spectra were dilution corrected to better display changes in fluorescence intensity upon lipid addition. See Tables 20-21 Appendix 
G for a summary of the different ratios of lipid to protein and the calcium concentration differences upon lipid addition. (A-C, D, 
F) Change in fluorescence intensity emission spectra upon lipid addition divided by fluorescence intensity prior to lipid addition (E) 
Change in fluorescence intensity of the donor emission of the 4 to 1 acceptor to donor experiment divided by the donor emission 
of the T1 donor alone experiment. 
The lack of observed FRET transfer may be due to an increased amount of protein and lipid 
aggregation making it difficult to detect changes in fluorescence. At the end of each of the 65% 
POPC, 5% PI(4,5)P2, 30% POPS FRET titrations experiments, the DLS Zetasizer was used to 
monitor aggregation in the solution. The entire solution was aggregated. Most trials had two broad 
peaks at 1489nm (97.3%) and 5384nm (2.7%), as shown in Fig. 6.10. If FRET transfer had 
occurred it would have been negligible because although the donor emission should was lower 
while the acceptor emission remained constant, the changes did not vary enough from the donor 
alone emission graphs. 
 
Figure 6.10: Size Distribution by Volume of the ANXA2 WT AlexaFluor 488 and AlexaFluor 568 after titration with 65% POPC 5% 
PI(4,5)P2 30% POPS. 
6.4 FRET Experiments with 55% POPC, 15% PI(4,5)P2, 30% POPS Lipid Composition 
In order to try to promote a FRET interaction, the percentage of PI(4,5)P2used to make the lipid 
films was raised to 15%, while maintaining the 4 to 1 acceptor to donor concentration ratio used 
in the previous experiments. Additionally, the calcium chloride was titrated instead of the lipids to 
determine whether lower calcium concentrations would promote a FRET interaction by lowering 
the amount of light scattering by lipids by reducing the amount of calcium available to promote 
aggregation. This was done by adding 0.5mM EGTA, which has a high affinity for chelating Ca2+, 
thus it removes any Ca2+ ions present in the solution, ensuring that the only Ca2+ ions present in 
the solution was the 10mM CaCl2 titrated into the solution.  
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Using Stanford’s Maxchelator, the amount of free calcium present in solution was calculated using 
a temperature of 20◦C, pH 7.4, and an ionic concentration of 0.15M. After adding the first 4uL of 
10mM CaCl2 to the titration there was 625uM of total CaCl2 in solution, approximately 468.77uM 
was bound and 156.22uM was free in solution. When 6uL of 10mM CaCl2 was added to the 
titration there was 909uM of total CaCl2 in solution, approximately 453.95uM was bound and 
455.04uM was free in solution. Adding 8uL 10mM CaCl2 resulted in 1176uM (1.176mM) of total 
CaCl2 in solution, approximately 441.00uM was bound and 735.02uM was free in solution. 10uL 
10mM CaCl2 resulted in 1,429uM (1.429mM) of total CaCl2 in solution, approximately 429.00uM 
was bound and 1,000uM (1mM) was free in solution. 12uL 10mM CaCl2 resulted in 1,667uM 
(1.667mM) of total CaCl2 in solution, approximately 417.00uM was bound and 1,250.00uM 
(1.250mM) was free in solution. Finally, 14uL 10mM CaCl2 resulted in 1,892uM (1.892mM) of 
total CaCl2 in solution, approximately 405.00uM was bound and 1487.00uM (1.487mM) was free 
in solution. Thus overall in these experiments the concentration of free Ca2+ ions ranged from 0uM-
1.487mM, and after the first 6uL of 10mM CaCl2 was added, the concentration of free Ca
2+ ions 
was higher than in the previous experiments of approximately 0.5mM CaCl2 throughout the 
titration. Tables 22 and 23 in Appendix G, will show the exact CaCl2, EGTA, donor, acceptor, and 
lipid concentrations used in these experiments. 
These experiments further verified that no FRET transfer was occurring, as indicated by the 
dilution corrected graphs of the change in fluorescence intensity of the emission spectra upon 
CaCl2 addition in Fig. 6.11, below. These titrations appeared to minimize lipid scattering, 
producing a flat line when dividing the fluorescence intensity of the donor emission upon CaCl2 
addition by the fluorescence intensity of the donor emission prior to CaCl2 addition (Fig.6.11D). 
The values plotted in Fig. 6.11D can be found in Tables 7 and 8, Appendix F. T1 saw the highest 
decrease in donor emission which was on average 88.5% of the donor emission prior to CaCl2 
addition, an 11.5% overall decrease in fluorescence intensity of the donor emission, while the 
acceptor emission experienced a decrease of approximately 5%, suggesting that this change was 
not due to FRET transfer.  
By averaging all the trials, the change in fluorescence intensity of the donor emission showed a 
1% increase in the fluorescence intensity of the donor emission compared to the fluorescence 
intensity before CaCl2 addition, and the acceptor emission experienced a 2% increase. The donor 
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alone titration, saw an average increase of approximately 9% in the donor emission fluorescence 
intensity and the acceptor emission has an 11% increase, which suggests that initially adding 75uM 
55% POPC 15% PI(4,5)P2, 30% POPS as the calcium aggregates the lipids this somehow makes the 
ANXA2 fluorophores more visible when the solution is scanned, likely because the aggregated 
lipid is sinking to the bottom of the cuvette. By definition, the ANXA2 protein should facilitate 
this aggregation process and it should also sink to the bottom of the cuvette. Thus, it seems, that 
the aggregated vesicles have the ANXA2 bound to them, with the N-terminal domains facing 
outwards, and the cuvette was mixed enough prior to the scan, allowing the aggregated protein to 
be scanned while the ANXA2 is still floating in the aqueous phase didn’t sink.  Additionally, 
decreasing the lipid to protein ratio from 30 to 15.6 throughout the titration, would make the 
fluorescently labeled ANXA2 more visible.  
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In order to better monitor the presence of lipid and ANXA2 aggregation, at the end of each titration 
the sample was scanned with the DLS using the Zetasizer software as shown in Fig. 6.12, below. 
There were two peaks the lipid peak was 109.7nm and it made up 55.20% of the solution and the 
aggregation peak was 2138nm and comprised 44.8% of the solution, thus about half of the solution 
was aggregated. The aggregation level is higher than the 95% POPC, 5% PI(4,5)P2 trial but much 
less than the 65% POPC, 5% PI(4,5)P2, 30% POPS trial. The lowered presence of aggregation upon 
increasing the concentration of PI(4,5)P2, suggested that the signal was less affected by light 
scattering produced by lipids.  
Figure 6.11: 55% POPC 15% PI(4,5)P2 30% POPS 4 to 1 Acceptor to Donor Calcium Chloride Titration.  Starting concentration: 0.5uM donor AlexaFluor 488 
ANXA2, 2.0uM acceptor AlexaFluor 568 ANXA2, 0.5mM EGTA.  The emission spectra were dilution corrected to better display changes in fluorescence intensity 
upon lipid addition. See Tables 22 and 23 Appendix G for a summary of the different ratios of lipid to protein and the EGTA concentration alterations upon 
calcium chloride addition. (A-C, E-F) Change in the fluorescence intensity of the emission spectra upon CaCl2 addition (D) Change in the fluorescence intensity 
of the donor emission of the 4 to 1 acceptor to donoe experiments upon CaCl2 addition divided by the donor emission prior to CaCl2 emission 
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Figure 6.12: Size Distribution by Volume of the ANXA2 WT AlexaFluor 488 and AlexaFluor 568 after titration with 55% POPC 15% 
PI(4,5)P2 30% POPS. 
6.5 FRET Experiments with 85% POPC, 15% PI(4,5)P2 Lipid Composition 
In order to further see how PI(4,5)P2affected FRET transfer, the next series of experiments remove 
POPC from the system while maintaining an elevated level of PI(4,5)P2 (85% POPC 15% PI(4,5)P2) 
and the 4 to 1 ANXA2 acceptor to donor concentration. Lipid and CaCl2 titrations were performed 
in order to compare the results from each. The CaCl2 titration used the same range of free Ca
2+ 
ions (0uM-1.487mM) as the 55% POPC 15% PI(4,5)P2, 30% POPS CaCl2 titration. The exact 
concentrations of lipid, acceptor ANXA2, donor ANXA2, EGTA, and calcium, as well as the lipid 
to protein ratio can be found in Table 24-25 Appendix G for the CaCl2 titration and Table 26-27 
Appendix G for the lipid titration. 
The CaCl2 titration bore similar results to the 65% POPC 5% PI(4,5)P2, 30% POPS CaCl2 titration. 
The first trial showed the strongest decrease in the donor emission upon CaCl2 addition. The 
biggest decrease (approximately 24% lowered fluorescence intensity of the donor emission), 
displayed in Table 9) occurred in Trial 1 and the donor alone emissions when 8uL 10mM CaCl2 
was added which resulted in a total CaCl2 concentration of 1,176uM (1.176mM) with 
approximately 441.00uM was bound and 735.02uM was free in solution. In order to best show that 
there was no FRET transfer occurring, the donor emission of the 4 to 1 acceptor to donor titration 
trials upon CaCl2 addition was divided by the donor alone donor emission upon CaCl2 addition, as 
shown in Fig. 6.13, the tabulated values for this graph can be found in Table 10. Trial 2 and 3 
yielded flat lines around 1, indicating no FRET transfer occurred while Trial 1 had a small increase 
in slope between 4uL CaCl2 addition and 8uL, because these numbers are smaller than 1, there is 
a small decrease in the donor emission intensity at this location. This decrease falls around the 
time when the CaCl2 has fully bound the EGTA and is free in solution indicating that in some trials 
FRET transfer may have occurred. If FRET transfer occurred, the acceptor emission should have 
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increased noticeably, which it did not according to the graphs of the changes in the fluorescence 
intensity of the donor emission upon CaCl2 addition, Fig13A-C, therefore the light scattering by 
the lipids may influence the acceptor emission, or the FRET transfer is very transient and the scan 
speed was too slow (60nm/min) to register the FRET transfer. 
The 85% POPC 15% PI(4,5)P2 lipid titration further supported the belief that FRET transfer is not 
occurring. In this experiment the increase in lipid volume appears to have lowered the fluorescence 
intensity signal of the donor emission as shown in Fig.6.13E. In viewing the DLS data with the 
Zetasizer software (Fig. 6.14) to monitor aggregation after each titration, there were numerous 
peaks and high amounts of aggregation.  In one trial, the lipid peak ran high at 151nm and it 
comprised 9.7% of the solution, 77% of the solution was aggregated in 1,740nm clusters, and the 
remaining 3.2% of the solution aggregated in giant 5,225nm clumps. It is highly likely that the 
Figure 6.13:  85% POPC 15% PI(4,5)P2 4 to 1 Acceptor to Donor Calcium Chloride Titration.  Starting concentration: 0.5uM donor AlexaFluor 
488 ANXA2, 2.0uM acceptor AlexaFluor 568 ANXA2, 0.5mM EGTA.  The emission spectra were dilution corrected to better display changes in 
fluorescence intensity upon lipid addition. See Tables 24-25 Appendix G for a summary of the different ratios of lipid to protein and the EGTA 
concentration alterations upon calcium chloride addition. (A-D) Change in the fluorescence intensity of the emission spectra upon CaCl2 addition 
(E) Change in the fluorescence intensity of the donor emission of the 4 to 1 acceptor to donor experiments upon CaCl2 addition divided by the 
donor emission prior to CaCl2 emission (F) Change in the fluorescence intensity of the donor emission of the 4 to 1 acceptor to donor experiments 
upon CaCl2 addition divided by the donor emission of the donor alone experiments. 
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aggregation will cause bigger particle size over time. This discovery supports the belief that light 
scattering by lipids caused the steady decrease in donor fluorescence. It was originally expected 
that increasing the PI(4,5)P2 would produce two clear peaks (lipid and aggregation) as observed in 
the 95% POPC 5% PI(4,5)P2 graph, instead it appears that the presence of a high enough 
concentration of either PI(4,5)P2of POPS will produce high amounts of aggregation regardless of 
lipid type. 
 
Figure 6.14: Size Distribution by Volume of the ANXA2 WT AlexaFluor 488 and AlexaFluor 568 after titration with 85% POPC 15% 
PI(4,5)P2 
 The lowered donor emission fluorescence signal appears to directly correlate with the increase in 
lipid vesicle concentration. Fig. 6.15A, C and D and the acceptor emission peak does not decrease 
as significantly compared to the donor emission suggesting that FRET transfer may be occurring. 
If FRET transfer is taking place the signal is low. The donor alone emission fluorescence intensity 
decreased an average of 82% of the donor emission signal prior to lipid addition (18% less 
fluorescence), with the lowest decrease in signal (65% 35% less fluorescence) occurring when 
18uL of 85% POPC, 5% PI(4,5)P2 (69.23uM, Table 26 Appendix G), as shown in Table 11. 
Similarly, Trial 1 experienced an average decrease in the donor emission fluorescence intensity 
divided by the donor emission fluorescence intensity prior to lipid addition of approximately 79% 
(21% less fluorescence) with the lowest decrease in signal (63%, 37% less fluorescence) occurring 
when 15uL of 85% POPC, 5% PI(4,5)P2 (60.0uM, Table 27 Appendix G). Therefore, it seems that 
about 3% of the decrease in fluorescence intensity could have resulted from a FRET transfer, which 
is a very low possibility. 
 Trial 2 experienced an average decrease in the donor emission fluorescence intensity divided by 
the donor emission fluorescence intensity prior to lipid addition of approximately 80.5% (19.5% 
less fluorescence) with the lowest decrease in signal (65%, 35% less fluorescence) occurring when 
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18uL of 85% POPC, 15% PI(4,5)P2 (69.23uM, Table 27 Appendix G), as shown in Table 11. This 
graph is very similar to the donor alone graph and T1. The graph of the 4 to 1 acceptor to donor 
trials donor emission divided by the donor alone fluorescence intensity in Fig. 6.15F, indicated the 
unlikely possibility of FRET transfer because these graphs should have had a decreasing slope if 
FRET transfer is occurring, because values higher than 1 indicate that the 4 to 1 trial had a higher 
fluorescence emission than the donor alone graph. 
 Thus Trial 3, which shows a flat line with an increase in slope towards the end of the titration 
likely did not experience FRET transfer. These findings seem to contradict the 4 to 1 acceptor to 
donor lipid titration with 95% POPC and 5% PI(4,5)P2which suggests that FRET transfer does 
occur. Even so, both experiments show decreases in the donor emission fluorescence intensity of 
approximately 30%. The 95% POPC 5% PI(4,5)P2trial showed an immediate decrease of 39% in 
donor fluorescence (Table 3) and then the fluorescence intensity leveled out suggesting that the 
donor had been quenched immediately.  This difference is likely because the 95% POPC 5% 
PI(4,5)P2trial had a acceptor concentration of 1uM and a donor concentration of 0.25uM while the 
85% POPC, 15% PI(4,5)P2 trial had an acceptor concentration of 2.0uM and a donor concentration 
of 0.5uM. Therefore, the lipid to protein ratio was higher in the 95% POPC 5% PI(4,5)P2trial and 
donor quenching may have occurred faster and was thus easier to detect. In the future, lower 
concentrations of acceptor and donor should be used to monitor this difference.  
In 2005, Patel et al. found that at high ANXA2 concentrations the likelihood of chance co-
localization increases, which can give the false appearance of FRET transfer. There is also a 
possibility that FRET transfer is not occurring and the donor fluorophore may be burying itself in 
the membrane. In 2008, Zibouche et al. observed FRET transfer between the fluorescently labeled 
the N-terminal domain of ANXA2 and fluorescently labeled phospholipids (POPS/POPC), which 
suggests that there is a direct interaction between ANXA2 and anionic phospholipids. Zibouche et 
al. (2008) also observed interactions between neighboring annexins, which suggests that there may 
be mixed roles for the N-terminal domain depending on how many ANXA2 molecules are able to 
bind to the anionic phospholipids. The acceptor (ANXA2 568) may not experience a similar 
decrease in fluorescence intensity because the acceptor is bigger (880.92g/mol) than the donor 
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(720.66g/mol) and it may alter the properties of ANXA2, preventing it from burying itself in the 
membrane. 
Figure 6.15: 85% POPC 15% PI(4,5)P2 4 to 1 Acceptor to Donor Lipid Titration.  Starting concentration: 0.5uM donor AlexaFluor 488 
ANXA2. 2.0uM acceptor AlexaFluor 568 ANXA2, 0.5mM calcium chloride.  The emission spectra were dilution corrected to better 
display changes in fluorescence intensity upon lipid addition. See Tables 26-27 Appendix G for a summary of the different ratios 
of lipid to protein and the calcium concentration differences upon lipid addition. (A-D) Change in the fluorescence intensity of the 
emission spectra upon lipid addition. (E) Change in the fluorescence intensity of the donor emission of the 4 to 1 acceptor to donor 
experiments upon lipid addition divided by the donor emission prior to lipid emission (F) Change in the fluorescence intensity of 
the donor emission of the 4 to 1 acceptor to donor experiments upon lipid addition divided by the donor emission of the donor 
alone experiments. 
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CHAPTER 7—CONCLUSIONS AND FUTURE WORK 
In summary, there was no significant FRET transfer observed between the N-terminal domains of 
adjacent ANXA2 acceptor and donor proteins with any lipid composition used. Protein and lipid 
aggregation and light scattering by lipids was observed and may have clouded the FRET signal. 
Alternatively, the cysteine residue may be inaccessible due to interactions with anionic 
phospholipids in the membrane as was observed by Zibouche et al. (2008). At this point, it cannot 
be conclusively stated whether or not ANXA2 promotes domain formation by self-associating with 
the N-terminal domain of adjacent ANXA2 proteins upon binding anionic phospholipids.  
In the future, a different acceptor/donor pair with a larger Forster distance (R0) and better spectral 
overlap might yield different results. In these experiments, the acceptor labeled poorly and due to 
slight size differences in the acceptor and donor, it is possible that the AlexaFluor 568 C5 
maleimide dye altered the conformation and possibly the functionality of ANXA2. The FRET 
experiments could also be improved by using faster scan speeds and quicker mixing to improve 
the probability of observing a FRET signal before the ANXA2 proteins and the lipids aggregate 
and sink to the bottom of the cuvette. Additionally, co-pelleting assays should be performed to 
ensure that the fluorescently labeled ANXA2 is functional. Acceptor alone controls should be done 
in order to better observe how light scattering by lipids effects the acceptor emission. When the 
experimental setup is fully optimized, it would be interesting to alter the pH instead of the calcium 
concentration because Illien et al. (2012) observed that in the absence of calcium, ANXA2 can 
aggregate membranes containing POPS and PI(4,5)P2 at acidic pH. Ultimately, the best method to 
monitor this interaction, would be to perform FCS-FLIM experiments in cells. 
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CHAPTER 8—APPENDIX 
8.1 Appendix A: ANXA2 6X and 10x Primers for Mutation 
6x Mutations 
K81A (AAGGCG) 
K81A_For: 5' CCAGAGAAGGACCAAAGCGGAACTTGCATCAGCAC 3' 
K81A_Rev: 5' GTGCTGATGCAAGTTCCGCTTTGGTCCTTCTCTGG 3' 
E189K (GAAAAA) 
E189K_For: 5' GGCTCTGTCATTGATTATAAACTGATTGACCAAGATGCTC 3' 
E189K_Rev: 5' GAGCATCTTGGTCAATCAGTTTATAATCAATGACAGAGCC 3' 
K206A (AAAGCA) 
K206A_For: 5' CGCTGGAGTGAAGAGGGCAGGAACTGATGTTCCC 3' 
K206A_Rev: 5' GGGAACATCAGTTCCTGCCCTCTTCACTCCAGCG 3' 
 
R196S (CGGAGT) 
R196S_For: 5' CTGATTGACCAAGATGCTAGTGATCTCTATGACGCTGGAG 3' 
R196S_Rev: 5' CTCCAGCGTCATAGAGATCACTAGCATCTTGGTCAATCAG 3' 
E219K (GAGAAG) 
E219K_For: 5' ATCAGCATCATGACCAAGCGGAGCGTGCCC 3' 
E219K_Rev: 5' GGGCACGCTCCGCTTGGTCATGATGCTGAT 3' 
K212S (AAGTCG)  
K212S_For_N: 5' CAGGAACTGATGTTCCCTCGTGGATCAGCATCATG 3' 
K212S_Rev_N: 5' CATGATGCTGATCCACGAGGGAACATCAGTTCCTG 3' 
Additional 10x Mutations 
R36→S (CGG→AGC) 
R36S_For: 5` TATACTAACTTTGATGCTGAGAGCGATGCTTTGAACATTGAAACA 3` 
R36s_Rev: 5` ATATGATTGAAACTACGACTCTCGCTACGAAACTTGTAACTTTGT 3` 
 
V53→A and T54→A (GTC→GCC and ACC→GCC) 
For_5` CAAAGGTGTGGATGAGGCCGCCATTGTCAACATTTTG 3` 
Rev_5` CAAAATGTTGACAATGGCGGCCTCATCCACACCTTTG 3` 
 
K328→A (AAA→GCA) 
K328A_For 5` TAAGGGCGACTACCAGGCAGCGCTGCTGTACCTG 3` 
K328A_Rev 5` AGGTACAGCAGCGCTGCCTGGTAGTCGCCCTTAG 3` 
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8.2 Appendix B: pSE420 Vector Map and ANXA2 Insertion Information 
 
pse420 Detailed Sequence 
ID   PSE420     preliminary; circular DNA; SYN; 4613 BP. 
XX 
AC   IG1117; 
DE   E. coli plasmid vector pSE420 - complete. 
XX 
KW   cloning vector. 
XX 
OS   Cloning vector 
OC   Artificial sequences; Cloning vehicles. 
XX 
RN   [1] 
RC   pRSETA from pET-3 & pBluescript series 
RC   pRSETB from pET-3 & pBluescript series 
RC   pRSETC from pET-3 & pBluescript series 
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RC   pSE280 from pKK233-2 
RC   pSE380 from pTrc99A 
RC   pSE420 from pSE380 
RC   pTRCHISA from pSE420 
RC   pTRCHISB from pSE420 
RC   pTRCHISC from pSE420 
RA   Abdel-Malek H.; 
RT   ; 
RL   The Digest 4:1-3(1991). 
XX 
RN   [2] 
RC   pKK421-1 from pKK233-2 
RC   pSLD7, pSLE1, pSLF1, pSLJ10 from pBluescript KS+ 
RC   pSL180 from pUC18 & linker 
RC   pSL189 from pUC19 & linker 
RC   pSL190 from pSL189 
RC   pSL1180 from pUC118 & linker 
RC   pSL1190 from pUC119 & linker 
RC   pSL300 from pSLJ10 & linker 
RC   pSL250 from pSL300 
RC   pSL260 from pSL250 
RC   pSL270 from pSL250 
RC   pSL251 from pSL250 
RC   pSL261 from pSL260 
RC   pSL271 from pSL270 
RC   pSL301 from pSL300 
RC   pSE1200 from pUC120 & linker 
RC   pSE1201 from pUC120 & linker 
RC   pSE1202 from pUC120 & linker 
RC   pSE219 from pKK233-2 
RC   pSE220 from pSE219 
RC   pSE280 from pKK421-1 
RC   pSE380 from pTrc99A 
RA   Brosius J.; 
RT   "Superpolylinkers in cloning and expression vectors"; 
RL   DNA 8:759-777(1989). 
XX 
CC   NM (pSE420) 
CC   CM (yes) 
CC   NA (ds-DNA) 
CC   TP (circular) 
CC   ST () 
CC   TY (plasmid) 
CC   SP (Invitrogen) 
CC   HO (E.coli NM522)(E.coli INValphaF') 
CC   CP () 
CC   FN (expression) 
CC   SE () 
CC   PA (pSE380) 
CC   BR () 
CC   OF () 
CC   OR () 
XX 
FH   Key             Location/Qualifiers 
FH 
FT   misc_feature    0..0 
FT                   /note="1. pSE380 4476bp 
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FT                   -> pSE420 4613bp" 
FT   promoter        0..0 
FT                   /note="PRO E. coli trc (trp & lac)" 
FT   promoter        0..0 
FT                   /note="PRO E. coli lacO gene" 
FT   promoter        0..0 
FT                   /note="PRO E. coli antitermination" 
FT   RBS             0..0 
FT                   /note="RBS E. coli g10 gene" 
FT   misc_feature    0..0 
FT                   /note="E. coli mini-cistron" 
FT   misc_feature    0..0 
FT                   /note="ATG" 
FT   promoter        0..0 
FT                   /note="PRO bacteriophage T7" 
FT   misc_binding    0..0 
FT                   /note="MCS SL2 superlinker" 
FT   promoter        0..0 
FT                   /note="PRO bacteriophage T3" 
FT   terminator      0..0 
FT                   /note="TER" 
FT   CDS             0..0 
FT                   /note="ANT E. coli beta-lactamase gene (bla) 
FT                   ampicillin resistance gene (apr/amp)" 
FT   rep_origin      0..0 
FT                   /note="ORI E. coli pMB1 (ColE1 and pBR322)" 
FT   promoter        0..0 
FT                   /note="PRO E. coli lacIq gene" 
XX 
SQ   Sequence 4613 BP; 1132 A; 1154 C; 1225 G; 1102 T; 0 other; 
     gtttgacagc ttatcatcga ctgcacggtg caccaatgct tctggcgtca ggcagccatc 
     ggaagctgtg gtatggctgt gcaggtcgta aatcactgca taattcgtgt cgctcaaggc 
     gcactcccgt tctggataat gttttttgcg ccgacatcat aacggttctg gcaaatattc 
     tgaaatgagc tgttgacaat taatcatccg gctcgtataa tgtgtggaat tgtgagcgga 
     taacaatttc acacaggaaa cagcgccgct gagaaaaagc gaagcggcac tgctctttaa 
     caatttatca gacaatctgt gtgggcactc gaccggaatt atcgattaac tttattatta 
     aaaattaaag aggtatatat taatgtatcg attaaataag gaggaataaa ccatggctgg 
     tgaccacgtc gtggaatgcc ttcgaattca gcacctgcac atgggacgtc gacctgaggt 
     aattataacc cgggccctat atatggatcc aattgcaatg atcatcatga cagatctgcg 
     cgcgatcgat atcagcgctt taaatttgcg catgctagct atagttctag aggtaccggt 
     tgttaacgtt agccggctac gtatactccg gaatattaat aggcctagga tgcatatggc 
     ggccgcctgc agctggcgcc atcgatacgc gtacgtcgcg accgcggaca tgtacagagc 
     tcgagaagta ctagtggcca cgtgggccgt gcaccttaag cttggctgtt ttggcggatg 
     agagaagatt ttcagcctga tacagattaa atcagaacgc agaagcggtc tgataaaaca 
     gaatttgcct ggcggcagta gcgcggtggt cccacctgac cccatgccga actcagaagt 
     gaaacgccgt agcgccgatg gtagtgtggg gtctccccat gcgagagtag ggaactgcca 
     ggcatcaaat aaaacgaaag gctcagtcga aagactgggc ctttcgtttt atctgttgtt 
     tgtcggtgaa cgctctcctg agtaggacaa atccgccggg agcggatttg aacgttgcga 
     agcaacggcc cggagggtgg cgggcaggac gcccgccata aactgccagg catcaaatta 
     agcagaaggc catcctgacg gatggccttt ttgcgtttct acaaactctt tttgtttatt 
     tttctaaata cattcaaata tgtatccgct catgagacaa taaccctgat aaatgcttca 
     ataatattga aaaaggaaga gtatgagtat tcaacatttc cgtgtcgccc ttattccctt 
     ttttgcggca ttttgccttc ctgtttttgc tcacccagaa acgctggtga aagtaaaaga 
     tgctgaagat cagttgggtg cacgagtggg ttacatcgaa ctggatctca acagcggtaa 
     gatccttgag agttttcgcc ccgaagaacg ttttccaatg atgagcactt ttaaagttct 
     gctatgtggc gcggtattat cccgtgttga cgccgggcaa gagcaactcg gtcgccgcat 
     acactattct cagaatgact tggttgagta ctcaccagtc acagaaaagc atcttacgga 
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     tggcatgaca gtaagagaat tatgcagtgc tgccataacc atgagtgata acactgcggc 
     caacttactt ctgacaacga tcggaggacc gaaggagcta accgcttttt tgcacaacat 
     gggggatcat gtaactcgcc ttgatcgttg ggaaccggag ctgaatgaag ccataccaaa 
     cgacgagcgt gacaccacga tgcctgtagc aatggcaaca acgttgcgca aactattaac 
     tggcgaacta cttactctag cttcccggca acaattaata gactggatgg aggcggataa 
     agttgcagga ccacttctgc gctcggccct tccggctggc tggtttattg ctgataaatc 
     tggagccggt gagcgtgggt ctcgcggtat cattgcagca ctggggccag atggtaagcc 
     ctcccgtatc gtagttatct acacgacggg gagtcaggca actatggatg aacgaaatag 
     acagatcgct gagataggtg cctcactgat taagcattgg taactgtcag accaagttta 
     ctcatatata ctttagattg atttaaaact tcatttttaa tttaaaagga tctaggtgaa 
     gatccttttt gataatctca tgaccaaaat cccttaacgt gagttttcgt tccactgagc 
     gtcagacccc gtagaaaaga tcaaaggatc ttcttgagat cctttttttc tgcgcgtaat 
     ctgctgcttg caaacaaaaa aaccaccgct accagcggtg gtttgtttgc cggatcaaga 
     gctaccaact ctttttccga aggtaactgg cttcagcaga gcgcagatac caaatactgt 
     ccttctagtg tagccgtagt taggccacca cttcaagaac tctgtagcac cgcctacata 
     cctcgctctg ctaatcctgt taccagtggc tgctgccagt ggcgataagt cgtgtcttac 
     cgggttggac tcaagacgat agttaccgga taaggcgcag cggtcgggct gaacgggggg 
     ttcgtgcaca cagcccagct tggagcgaac gacctacacc gaactgagat acctacagcg 
     tgagctatga gaaagcgcca cgcttcccga agggagaaag gcggacaggt atccggtaag 
     cggcagggtc ggaacaggag agcgcacgag ggagcttcca gggggaaacg cctggtatct 
     ttatagtcct gtcgggtttc gccacctctg acttgagcgt cgatttttgt gatgctcgtc 
     aggggggcgg agcctatgga aaaacgccag caacgcggcc tttttacggt tcctggcctt 
     ttgctggcct tttgctcaca tgttctttcc tgcgttatcc cctgattctg tggataaccg 
     tattaccgcc tttgagtgag ctgataccgc tcgccgcagc cgaacgaccg agcgcagcga 
     gtcagtgagc gaggaagcgg aagagcgcct gatgcggtat tttctcctta cgcatctgtg 
     cggtatttca caccgcatat ggtgcactct cagtacaatc tgctctgatg ccgcatagtt 
     aagccagtat acactccgct atcgctacgt gactgggtca tggctgcgcc ccgacacccg 
     ccaacacccg ctgacgcgcc ctgacgggct tgtctgctcc cggcatccgc ttacagacaa 
     gctgtgaccg tctccgggag ctgcatgtgt cagaggtttt caccgtcatc accgaaacgc 
     gcgaggcagc agatcaattc gcgcgcgaag gcgaagcggc atgcatttac gttgacacca 
     tcgaatggcg caaaaccttt cgcggtatgg catgatagcg cccggaagag agtcaattca 
     gggtggtgaa tgtgaaacca gtaacgttat acgatgtcgc agagtatgcc ggtgtctctt 
     atcagaccgt ttcccgcgtg gtgaaccagg ccagccacgt ttctgcgaaa acgcgggaaa 
     aagtggaagc ggcgatggcg gagctgaatt acattcccaa ccgcgtggca caacaactgg 
     cgggcaaaca gtcgttgctg attggcgttg ccacctccag tctggccctg cacgcgccgt 
     cgcaaattgt cgcggcgatt aaatctcgcg ccgatcaact gggtgccagc gtggtggtgt 
     cgatggtaga acgaagcggc gtcgaagcct gtaaagcggc ggtgcacaat cttctcgcgc 
     aacgcgtcag tgggctgatc attaactatc cgctggatga ccaggatgcc attgctgtgg 
     aagctgcctg cactaatgtt ccggcgttat ttcttgatgt ctctgaccag acacccatca 
     acagtattat tttctcccat gaagacggta cgcgactggg cgtggagcat ctggtcgcat 
     tgggtcacca gcaaatcgcg ctgttagcgg gcccattaag ttctgtctcg gcgcgtctgc 
     gtctggctgg ctggcataaa tatctcactc gcaatcaaat tcagccgata gcggaacggg 
     aaggcgactg gagtgccatg tccggttttc aacaaaccat gcaaatgctg aatgagggca 
     tcgttcccac tgcgatgctg gttgccaacg atcagatggc gctgggcgca atgcgcgcca 
     ttaccgagtc cgggctgcgc gttggtgcgg atatctcggt agtgggatac gacgataccg 
     aagacagctc atgttatatc ccgccgtcaa ccaccatcaa acaggatttt cgcctgctgg 
     ggcaaaccag cgtggaccgc ttgctgcaac tctctcaggg ccaggcggtg aagggcaatc 
     agctgttgcc cgtctcactg gtgaaaagaa aaaccaccct ggcgcccaat acgcaaaccg 
     cctctccccg cgcgttggcc gattcattaa tgcagctggc acgacaggtt tcccgactgg 
     aaagcgggca gtgagcgcaa cgcaattaat gtgagttagc gcgaattgat ctg 
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8.3 APPENDIX C: FASTA DNA Sequence and Sequence Alignment Data 
FASTA: 
Homo sapiens annexin A2 (ANXA2), transcript variant 3, mRNA 
NCBI Reference Sequence: NM_004039.2 
GenBank Graphics  
 
>gi|50845389:56-1075 Homo sapiens annexin A2 (ANXA2), transcript variant 3, 
mRNA 
ATGTCTACTGTTCACGAAATCCTGTGCAAGCTCAGCTTGGAGGGTGATCACTCTACACCCCCAAGTGCAT 
ATGGGTCTGTCAAAGCCTATACTAACTTTGATGCTGAGCGGGATGCTTTGAACATTGAAACAGCCATCAA 
GACCAAAGGTGTGGATGAGGTCACCATTGTCAACATTTTGACCAACCGCAGCAATGCACAGAGACAGGAT 
ATTGCCTTCGCCTACCAGAGAAGGACCAAAAAGGAACTTGCATCAGCACTGAAGTCAGCCTTATCTGGCC 
ACCTGGAGACGGTGATTTTGGGCCTATTGAAGACACCTGCTCAGTATGACGCTTCTGAGCTAAAAGCTTC 
CATGAAGGGGCTGGGAACCGACGAGGACTCTCTCATTGAGATCATCTGCTCCAGAACCAACCAGGAGCTG 
CAGGAAATTAACAGAGTCTACAAGGAAATGTACAAGACTGATCTGGAGAAGGACATTATTTCGGACACAT 
CTGGTGACTTCCGCAAGCTGATGGTTGCCCTGGCAAAGGGTAGAAGAGCAGAGGATGGCTCTGTCATTGA 
TTATGAACTGATTGACCAAGATGCTCGGGATCTCTATGACGCTGGAGTGAAGAGGAAAGGAACTGATGTT 
CCCAAGTGGATCAGCATCATGACCGAGCGGAGCGTGCCCCACCTCCAGAAAGTATTTGATAGGTACAAGA 
GTTACAGCCCTTATGACATGTTGGAAAGCATCAGGAAAGAGGTTAAAGGAGACCTGGAAAATGCTTTCCT 
GAACCTGGTTCAGTGCATTCAGAACAAGCCCCTGTATTTTGCTGATCGGCTGTATGACTCCATGAAGGGC 
AAGGGGACGCGAGATAAGGTCCTGATCAGAATCATGGTCTCCCGCAGTGAAGTGGACATGTTGAAAATTA 
GGTCTGAATTCAAGAGAAAGTACGGCAAGTCCCTGTACTATTATATCCAGCAAGACACTAAGGGCGACTA 
CCAGAAAGCGCTGCTGTACCTGTGTGGTGGAGATGACTGA 
 
1020 bp with Methionine 
 
 
Anx A2 seq. 
PSE 420 Vector Seq. 
5'->3' : 5'-
ATGTCTACTGTTCACGAAATCCTGTGCAAGCTCAGCTTGGAGGGTGATCACTCTACACCCCCAAGTGCATATGGGT
CTGTCAAAGCCTATACTAACTTTGATGCTGAGCGGGATGCTTTGAACATTGAAACAGCCATCAAGACCAAAGGTGT
GGATGAGGTCACCATTGTCAACATTTTGACCAACCGCAGCAATGCACAGAGACAGGATATTGCCTTCGCCTACCAG
AGAAGGACCAAAAAGGAACTTGCATCAGCACTGAAGTCAGCCTTATCTGGCCACCTGGAGACGGTGATTTTGGGC
CTATTGAAGACACCTGCTCAGTATGACGCTTCTGAGCTAAAAGCTTCCATGAAGGGGCTGGGAACCGACGAGGAC
TCTCTCATTGAGATCATCTGCTCCAGAACCAACCAGGAGCTGCAGGAAATTAACAGAGTCTACAAGGAAATGTACA
AGACTGATCTGGAGAAGGACATTATTTCGGACACATCTGGTGACTTCCGCAAGCTGATGGTTGCCCTGGCAAAGG
GTAGAAGAGCAGAGGATGGCTCTGTCATTGATTATGAACTGATTGACCAAGATGCTCGGGATCTCTATGACGCTG
GAGTGAAGAGGAAAGGAACTGATGTTCCCAAGTGGATCAGCATCATGACCGAGCGGAGCGTGCCCCACCTCCAG
AAAGTATTTGATAGGTACAAGAGTTACAGCCCTTATGACATGTTGGAAAGCATCAGGAAAGAGGTTAAAGGAGAC
CTGGAAAATGCTTTCCTGAACCTGGTTCAGTGCATTCAGAACAAGCCCCTGTATTTTGCTGATCGGCTGTATGACTC
CATGAAGGGCAAGGGGACGCGAGATAAGGTCCTGATCAGAATCATGGTCTCCCGCAGTGAAGTGGACATGTTGA
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AAATTAGGTCTGAATTCAAGAGAAAGTACGGCAAGTCCCTGTACTATTATATCCAGCAAGACACTAAGGGCGACT
ACCAGAAAGCGCTGCTGTACCTGTGTGGTGGAGATGACTGAAGCTTGGCTGTTTTGGCGGATGAGAGAAGATTTT
CAGCCTGATACAGATTAAATCAGAACGCAGAAGCGGTCTGATAAAACAGAATTTGCCTGGCGGCAGTAGCGCGGT
GGTCCCACCTGACCCCATGCCGAACTCAGAAGTGAAACGCCGTAGCGCCGATGGTAGTGTGGGGTCTCCCCATGC
GAGAGTAGGGAACTGCCAGGCATCAAATAAAACGAAAGGCTCAGTCGAAAGACTGGGCCTTTCGTTTTATCTGTT
GTTTGTCGGTGAACGCTCTCCTGAGTAGGACAAATCCGCCGGGAGCGGATTTGAACGTTGCGAAGCAACGGCCCG
GAGGGTGGCGGGCAGGACGCCCGCCATAAACTGCCAGGCATCAAATTAAGCAGAAGGCCATCCTGACGGATGGC
CTTTTTGCGTTTCTACAAACTCTTTTTGTTTATTTTTCTAAATACATTCAAATATGTATCCGCTCATGAGACAATAACC
CTGATAAATGCTTCAATAATATTGAAAAAGGAAGAGTATGAGTATTCAACATTTCCGTGTCGCCCTTATTCCCTTTT
TTGCGGCATTTTGCCTTCCTGTTTTTGCTCACCCAGAAACGCTGGTGAAAGTAAAAGATGCTGAAGATCAGTTGGG
TGCACGAGTGGGTTACATCGAACTGGATCTCAACAGCGGTAAGATCCTTGAGAGTTTTCGCCCCGAAGAACGTTTT
CCAATGATGAGCACTTTTAAAGTTCTGCTATGTGGCGCGGTATTATCCCGTGTTGACGCCGGGCAAGAGCAACTCG
GTCGCCGCATACACTATTCTCAGAATGACTTGGTTGAGTACTCACCAGTCACAGAAAAGCATCTTACGGATGGCAT
GACAGTAAGAGAATTATGCAGTGCTGCCATAACCATGAGTGATAACACTGCGGCCAACTTACTTCTGACAACGATC
GGAGGACCGAAGGAGCTAACCGCTTTTTTGCACAACATGGGGGATCATGTAACTCGCCTTGATCGTTGGGAACCG
GAGCTGAATGAAGCCATACCAAACGACGAGCGTGACACCACGATGCCTGTAGCAATGGCAACAACGTTGCGCAA
ACTATTAACTGGCGAACTACTTACTCTAGCTTCCCGGCAACAATTAATAGACTGGATGGAGGCGGATAAAGTTGCA
GGACCACTTCTGCGCTCGGCCCTTCCGGCTGGCTGGTTTATTGCTGATAAATCTGGAGCCGGTGAGCGTGGGTCTC
GCGGTATCATTGCAGCACTGGGGCCAGATGGTAAGCCCTCCCGTATCGTAGTTATCTACACGACGGGGAGTCAGG
CAACTATGGATGAACGAAATAGACAGATCGCTGAGATAGGTGCCTCACTGATTAAGCATTGGTAACTGTCAGACC
AAGTTTACTCATATATACTTTAGATTGATTTAAAACTTCATTTTTAATTTAAAAGGATCTAGGTGAAGATCCTTTTTG
ATAATCTCATGACCAAAATCCCTTAACGTGAGTTTTCGTTCCACTGAGCGTCAGACCCCGTAGAAAAGATCAAAGG
ATCTTCTTGAGATCCTTTTTTTCTGCGCGTAATCTGCTGCTTGCAAACAAAAAAACCACCGCTACCAGCGGTGGTTT
GTTTGCCGGATCAAGAGCTACCAACTCTTTTTCCGAAGGTAACTGGCTTCAGCAGAGCGCAGATACCAAATACTGT
CCTTCTAGTGTAGCCGTAGTTAGGCCACCACTTCAAGAACTCTGTAGCACCGCCTACATACCTCGCTCTGCTAATCC
TGTTACCAGTGGCTGCTGCCAGTGGCGATAAGTCGTGTCTTACCGGGTTGGACTCAAGACGATAGTTACCGGATA
AGGCGCAGCGGTCGGGCTGAACGGGGGGTTCGTGCACACAGCCCAGCTTGGAGCGAACGACCTACACCGAACTG
AGATACCTACAGCGTGAGCTATGAGAAAGCGCCACGCTTCCCGAAGGGAGAAAGGCGGACAGGTATCCGGTAAG
CGGCAGGGTCGGAACAGGAGAGCGCACGAGGGAGCTTCCAGGGGGAAACGCCTGGTATCTTTATAGTCCTGTCG
GGTTTCGCCACCTCTGACTTGAGCGTCGATTTTTGTGATGCTCGTCAGGGGGGCGGAGCCTATGGAAAAACGCCA
GCAACGCGGCCTTTTTACGGTTCCTGGCCTTTTGCTGGCCTTTTGCTCACATGTTCTTTCCTGCGTTATCCCCTGATT
CTGTGGATAACCGTATTACCGCCTTTGAGTGAGCTGATACCGCTCGCCGCAGCCGAACGACCGAGCGCAGCGAGT
CAGTGAGCGAGGAAGCGGAAGAGCGCCTGATGCGGTATTTTCTCCTTACGCATCTGTGCGGTATTTCACACCGCAT
ATGGTGCACTCTCAGTACAATCTGCTCTGATGCCGCATAGTTAAGCCAGTATACACTCCGCTATCGCTACGTGACTG
GGTCATGGCTGCGCCCCGACACCCGCCAACACCCGCTGACGCGCCCTGACGGGCTTGTCTGCTCCCGGCATCCGCT
TACAGACAAGCTGTGACCGTCTCCGGGAGCTGCATGTGTCAGAGGTTTTCACCGTCATCACCGAAACGCGCGAGG
CAGCAGATCAATTCGCGCGCGAAGGCGAAGCGGCATGCATTTACGTTGACACCATCGAATGGCGCAAAACCTTTC
GCGGTATGGCATGATAGCGCCCGGAAGAGAGTCAATTCAGGGTGGTGAATGTGAAACCAGTAACGTTATACGAT
GTCGCAGAGTATGCCGGTGTCTCTTATCAGACCGTTTCCCGCGTGGTGAACCAGGCCAGCCACGTTTCTGCGAAAA
CGCGGGAAAAAGTGGAAGCGGCGATGGCGGAGCTGAATTACATTCCCAACCGCGTGGCACAACAACTGGCGGGC
AAACAGTCGTTGCTGATTGGCGTTGCCACCTCCAGTCTGGCCCTGCACGCGCCGTCGCAAATTGTCGCGGCGATTA
AATCTCGCGCCGATCAACTGGGTGCCAGCGTGGTGGTGTCGATGGTAGAACGAAGCGGCGTCGAAGCCTGTAAA
GCGGCGGTGCACAATCTTCTCGCGCAACGCGTCAGTGGGCTGATCATTAACTATCCGCTGGATGACCAGGATGCC
ATTGCTGTGGAAGCTGCCTGCACTAATGTTCCGGCGTTATTTCTTGATGTCTCTGACCAGACACCCATCAACAGTAT
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TATTTTCTCCCATGAAGACGGTACGCGACTGGGCGTGGAGCATCTGGTCGCATTGGGTCACCAGCAAATCGCGCT
GTTAGCGGGCCCATTAAGTTCTGTCTCGGCGCGTCTGCGTCTGGCTGGCTGGCATAAATATCTCACTCGCAATCAA
ATTCAGCCGATAGCGGAACGGGAAGGCGACTGGAGTGCCATGTCCGGTTTTCAACAAACCATGCAAATGCTGAAT
GAGGGCATCGTTCCCACTGCGATGCTGGTTGCCAACGATCAGATGGCGCTGGGCGCAATGCGCGCCATTACCGAG
TCCGGGCTGCGCGTTGGTGCGGATATCTCGGTAGTGGGATACGACGATACCGAAGACAGCTCATGTTATATCCCG
CCGTCAACCACCATCAAACAGGATTTTCGCCTGCTGGGGCAAACCAGCGTGGACCGCTTGCTGCAACTCTCTCAGG
GCCAGGCGGTGAAGGGCAATCAGCTGTTGCCCGTCTCACTGGTGAAAAGAAAAACCACCCTGGCGCCCAATACGC
AAACCGCCTCTCCCCGCGCGTTGGCCGATTCATTAATGCAGCTGGCACGACAGGTTTCCCGACTGGAAAGCGGGC
AGTGAGCGCAACGCAATTAATGTGAGTTAGCGCGAATTGATCTGGTTTGACAGCTTATCATCGACTGCACGGTGC
ACCAATGCTTCTGGCGTCAGGCAGCCATCGGAAGCTGTGGTATGGCTGTGCAGGTCGTAAATCACTGCATAATTC
GTGTCGCTCAAGGCGCACTCCCGTTCTGGATAATGTTTTTTGCGCCGACATCATAACGGTTCTGGCAAATATTCTGA
AATGAGCTGTTGACAATTAATCATCCGGCTCGTATAATGTGTGGAATTGTGAGCGGATAACAATTTCACACAGGAA
ACAGCGCCGCTGAGAAAAAGCGAAGCGGCACTGCTCTTTAACAATTTATCAGACAATCTGTGTGGGCACTCGACC
GGAATTATCGATTAACTTTATTATTAAAAATTAAAGAGGTATATATTAATGTATCGATTAAATAAGGAGGAATAAA
C -3' 
Sequence Alignment Data 
1. Anx WT 401-800 
5’TGCAGGAAATTAACAGAGTCTACAAGGAAATGTACAAGACTGATCTGGAGAAGG
ACATTATTTCGGACACATCTGGTGACTTCCGCAAGCTGATGGTTGCCCTGGCAAAGG
GTAGAAGAGCAGAGGATGGCTCTGTCATTGATTATGAACTGATTGACCAAGATGCTC
GGGATCTCTATGACGCTGGAGTGAAGAGGAAAGGAACTGATGTTCCCAAGTGGATC
AGCATCATGACCGAGCGGAGCGTGCCCCACCTCCAGAAAGTATTTGATAGGTACAA
GAGTTACAGCCCTTATGACATGTTGGAAAGCATCAGGAAAGAGGTTAAAGGAGACC
TGGAAAATGCTTTCCTGAACCTGGTTCAGTGCATTCAGAACAAGCCCCTGTATTTTG
CTGATCGGCTGTATGACTCCATGAAGGGCAAGGGGACGCGAGATAAGGTCCTGATC
AGAATCATGGTCTCCCGCAGTGAAGTGGACATGTTGAAAATTAGGTCTGAGTTCAAG
AGAAAGTACGGCAAGTCCCTGTACTATTATATCCAGCAAGACACTAAGGGCGACTA
CCAGAAAGCGCTGCTGTACCTGTGTGGTGGAGATGACTGAAGCCCGACACGGCCTG
AGCGTCCAGAAATGGTGCTCACCAAGCTTGGCTGTTTTGGCGGATGAGAGAAGATTT
TCAGCCTGATACAGATTAAATCAGAACGCAGAAGCGGTCTGATAAAACAGAATTTG
CCTGGCGGCAGTAGCGCGGTGGTCCCACCTGACCCATGCCGAACTCAGAAGTGAAA
CGCCGTAGCGCCGATGGTAGTGTGGGGTCTCCCCATGCGAGAGTAGGGAACTGCCA
GGCATCAAATAAAACGAAAGGCTCAGTCGAAAGACTGGGCTTTCGTTTTATCTGTTG
TTTGTCGGTGAACGCTCTCCTGAGTAGGACAAATCCGCCGGGAGCGGATTTGAACGT
TGCGAGCACGGCCCGGGAGGGTGGCGGGCAGGACGCCCGCATAAACTGCCAGGCAT
CAAATTAAGCAGAAGCATCCTGACGATGACTTTTGCGTTTCTACAACTCTTTTGTTAT
TTTTCTAATACATCAAATATGTATCGCTCATGAACATAACCCTGATAATGCTCAATA
ATATGAAAAGANNNTGATATCAATTTCNNTCGCCTTATCTTTGCGCATTGCTCTGTTT
GCTACCGAACGTNAGTAAGATGCTGAATCTTGGGTGCAGAGGTGNTACTCGACTGT
GATCTCCACAGCGGGTATGA 3’ 
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2.  ANXA2 WT 400-1 
>52F_002_AnxA2-WT_Anx-A21-400-1_F04  (32 .. 936 = 905_bp) 
TGAGAGAGTCCTCGTCGGTTCCCAGCCCCTTCATGGAAGCCTTTAGCTCAGAAGCGT
CATACTGAGCAGGTGTCTTCAATAGGCCCAAAATCACCGTCTCCAGGTGGCCAGATA
AGGCTGACTTCAGTGCTGATGCAAGTTCCTTTTTGGTCCTTCTCTGGTAGGCGAAGG
CAATATCCTGTCTCTGTTCATTGCTGCGGTTGGTCAAAATGTTGACAATGGTGACCTC
ATCCACACCTTTGGTCTTGATGGCTGTTTCAATGTTCAAAGCATCCCGCTCAGCATCA
AAGTTAGTATAGGCTTTGACAGACCCATATGCACTTGGGGGTGTAGAGTGATCACCC
TCCAAGCTGAGCTTGCACAGGATTTCGTGAACAGTAGACATGGTTTATTCCTCCTTA
TTTAATCGATACATTAATATATACCTCTTTAATTTTTAATAATAAAGTTAATCGATAA
TTCCGGTCGAGTGCCCACACAGATTGTCTGATAAATTGTTAAAGAGCAGTGCCGCTT
CGCTTTTTCTCAGCGGCGCTGTTTCCTGTGTGAAATTGTTATCCGCTCACAATTCCAC
ACATTATACGAGCCGGATGATTAATTGTCAACAGCTCATTTCAGAATATTTGCCAGA
ACCGTTATGATGTCGGCGCAAAAAACATTATCCAGAACGGGAGTGCGCCTTGAGCG
ACACGAATTATGCAGTGATTTACGACCTGCACAGCCATACCACAGCTTCCGATGGCT
GCCTGACGCCAGAAGCATTGGTGCACCGTGCAGTCGATGATAAGCTGTCAAACCAG
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ATCAATTCGCGCTAACTTACATTAATTGCGTTGCGCTCACTGCCCGCTTTCCAGTCGG
GAAACCTGTCGTGCCAGCTGCATTAATGAATCGGCCAACGCGCGGGG 
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8.4 Appendix D: Mass Spectrometry Analysis of ANXA2 Gel Band 
 
 
Figure 3: Mass Spectrometry Analysis of ANXA2 Gel Band by Dr. John Leszyk from the University of Massachusetts Medical 
School 
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8.5 Appendix E: Preliminary FRET Experiments  
In order to see whether removing PI(4,5)P2from the system effects FRET transfer, preliminary 
experiments were performed with a lipid composition of 70% POPC, 30% POPS and 100% POPC 
using a 2 to 1 acceptor to donor ratio.  The 100% POPC trials were intended to show the degree of 
light scattering by lipids that does not result from ANXA2-mediated aggregation, because POPC 
is a neutral lipid that does not bind ANXA2. The 70% POPC 30% POPS trials were meant to see 
if a FRET transfer occurs in the absence of PI(4,5)P2. In the future, these experiments should be 
repeated with a higher acceptor to donor ratio in order to better understand the role of the anionic 
phospholipid POPS in ANXA2 self-association. The 100% POPC experiments should be repeated 
to better understand the role of light scattering by lipids which does not result from aggregation 
because POPC is neutral and will not cluster in the presence of calcium or interact with ANXA2. 
 
Figure 8.2: 70% POPC 30% POPC 2 to 1 Acceptor to Donor Lipid Titration.  Starting concentration 0.5uM donor AlexaFluor 488 and 
0.5uM calcium chloride concentration was 0.5mM.  The emission spectra were dilution corrected to better display changes in 
fluorescence intensity upon lipid addition. See Tables 28-29 Appendix G for a summary of the different ratios of lipid to protein 
and the calcium concentration differences upon lipid addition. (A-B) Change in fluorescence intensity emission spectra upon lipid 
addition divided by fluorescence intensity prior to lipid addition (C-D) Change in Ratio of Fluorescence Intensity upon Lipid Addition, 
all values for each trial were divided by the fluorescence intensity when there were no lipids present. 
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Figure 8.3: 70% POPC 30% POPC 2 to 1 Acceptor to Donor Lipid Titration. Starting concentration 0.5uM donor AlexaFluor 488, 1.0uM acceptor ANXA2 568, 0.5uM 
calcium chloride concentration was 0.5mM.  The emission spectra were dilution corrected to better display changes in fluorescence intensity upon lipid addition. 
See Tables 30-31 Appendix G for a summary of the different ratios of lipid to protein and the calcium concentration differences upon lipid addition. (A-B) Change in 
fluorescence intensity emission spectra upon lipid addition divided by fluorescence intensity prior to lipid addition (C-D) Change in Ratio of Fluorescence Intensity 
upon Lipid Addition, all values for each trial were divided by the fluorescence intensity when there were no lipids present. 
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Figure 8.4: Size Distribution by Volume of the ANXA2 WT AlexaFluor 488 and AlexaFluor 568 after titration with 70% POPC 30% 
POPS 
 
 
 
Figure 8.5:  Size Distribution by Volume of the ANXA2 WT AlexaFluor 488 and AlexaFluor 568 after titration with 100% POPC 
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Figure 8.6: 100% POPC Donor Alone Lipid Titration.  Starting concentration: 0.5uM donor AlexaFluor 488 and 0.5uM calcium chloride concentration was 
0.5mM.  The emission spectra were dilution corrected to better display changes in fluorescence intensity upon lipid addition. See Appendix _ for a 
summary of the different ratios of lipid to protein and the calcium concentration differences upon lipid addition. (A-C) Change in fluorescence intensity 
emission spectra upon lipid addition divided by fluorescence intensity prior to lipid addition (D) Change in Ratio of Fluorescence Intensity upon Lipid 
Addition, all values for each trial were divided by the fluorescence intensity when there were no lipids present. 
Figure 8.7: 100% POPC 2 to 1 Acceptor to Donor Lipid Titration.  I Starting concentration 0.5uM donor AlexaFluor 488, 1.0uM acceptor ANXA2 568, and 0.5uM 
calcium chloride concentration was 0.5mM.  The emission spectra were dilution corrected to better display changes in fluorescence intensity upon lipid addition. 
See Tables 32-33 Appendix G for a summary of the different ratios of lipid to protein and the calcium concentration differences upon lipid addition. (A-C) Change 
in fluorescence intensity emission spectra upon lipid addition divided by fluorescence intensity prior to lipid addition (D) Change in Ratio of Fluorescence Intensity 
upon Lipid Addition, all values for each trial were divided by the fluorescence intensity when there were no lipids present. 
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8.6 Appendix F: Tables of Compiled FRET Data for Each Titration 
Table 1: Change in Donor Emission Fluorescence Intensity Upon 95% POPC 5% PI(4,5)P2 Lipid Addition,  Donor Alone 
  
 
 
 
 
 
 
Table 2: Change in Fluorescence Intensity Upon 95% POPC 5% PI(4,5)P2 Lipid Addition, 3 to 1 Donor to Acceptor 
  
 
 
 
 
 
 
 
 
 
Table 3: Change in Fluorescence Intensity Upon 95% POPC 5% PI(4,5)P2 Lipid Addition, 4 to 1 Acceptor to Donor 
 
 
 
 
 
 
Volume of 95% POPC 
5% PI(4,5)P2 Added T1 T2 T3 
0 1 1 1 
3 0.9183 0.93239 0.9256 
6 0.7636 0.8082 0.9601 
9 0.9609 0.8332 0.8958 
12 0.8352 0.8790 0.9179 
15 0.8854 0.7855 0.9129 
18 0.9034 0.8681 0.9371 
Average Change 0.8953 0.8723 0.9356 
Volume of 95% 
POPC 5% PI(4,5)P2 
Added 
T1 Donor 
Emission 
T1 
Acceptor 
Emission 
T2 Donor 
Emission 
T2 
Acceptor 
Emission 
0 1 1 1 1 
3 1.0245 1.004 0.9127 0.9834 
6 0.9376 0.9906 0.9605 1.0284 
9 0.9552 1.0142 0.8790 1.0149 
12 1.1020 1.1371 0.8836 1.0336 
15 0.9211 1.0474 0.9632 1.1179 
18 0.8891 1.0923 0.8984 1.0785 
Average Change 0.9756 1.0408 0.9282 1.0367 
Volume of 95% POPC 5% 
PI(4,5)P2 Added 
T1 Donor 
Emission 
T1 Acceptor 
Emission 
0 1 1 
3 0.6102 1.0893 
6 0.6392 1.1412 
9 0.6710 1.1233 
12 0.6406 1.1273 
Average Change 0.7122 1.0962 
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 Table 4: Change Fluorescence Intensity Donor Emission Upon 65% POPC 5% PI(4,5)P2 30% POPS Lipid Addition, 4 to 1 Acceptor 
to Donor 
 
 
 
Table 5: Change Fluorescence Intensity Acceptor Emission Upon 65% POPC 5% PI(4,5)P2 30% POPS Lipid Addition, 4 to 1 
Acceptor to Donor 
   
Volume of 65% 
POPC 5% 
PI(4,5)P2 
30% POPS 
Added 
T1 Donor 
Alone 
T2 
Donor 
Alone 
T1 T2 T3 
0 1 1 1 1 1 
3 0.9621 0.9315 0.7690 0.9705 0.8146 
6 0.9052 1.0245 0.8516 0.8904 0.9329 
9 0.8082 0.9874 0.6081 0.8006 0.8436 
12 0.8433 0.9078 0.7898 0.9159 0.7480 
15 0.8900 - 0.7917 0.8717 0.8312 
Average Change 0.9015 0.9702 0.8017 0.9082 0.8617 
Volume of 65% 
POPC 15% 
PI(4,5)P2 30% 
POPS Added 
T1 Donor 
Alone 
T2 
Donor 
Alone 
T1 T2 T3 
0 1 1 1 1 1 
3 1.0067 1.0102 0.8910 0.9932 0.8915 
6 1.0094 1.0182 0.9478 0.9321 0.9645 
9 0.9829 1.0488 0.7824 0.8849 0.9512 
12 1.0256 1.0762 0.9200 0.9937 0.8758 
15 1.1251 - 0.8717 0.9707 0.9909 
Average 
Change 
1.0250 1.0307 0.9022 0.9624 0.9457 
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 Table 6: Change in Fluorescence Intensity of the Donor Emission Divided by the T1 Donor Alone Change in Fluorescence 
Intensity, 4 to 1 Acceptor to Donor, 65% POPC 5% PI(4,5)P2 30% POPS 
 
Table 7: Change Fluorescence Intensity Acceptor Emission Upon Calcium Chloride Addition, 4 to 1 Acceptor to Donor, 55% 
POPC15% PI(4,5)P2 30% POPS 
 
Table 8: Change Fluorescence Intensity Donor Emission Upon Calcium Chloride Lipid Addition, 4 to 1 Acceptor to Donor, 55% 
POPC 15% PI(4,5)P2 30% POPS 
Volume of 65% POPC 
15% PI(4,5)P2 30% 
POPS Added 
T1 T2 T3 
0 0.9312 1.1924 0.723 
3 0.7443 1.2028 0.6141 
6 0.8761 1.1729 0.7474 
9 0.7006 1.1812 0.7570 
12 0.8721 1.2951 0.6433 
15 0.8288 1.1685 0.9780 
Average Change 0.8255 1.2022 1.8793 
Volume of 10m 
CaCl2 Added 
Donor 
Alone 
T1 T2 T3 T4 
0 1 1 1 1 1 
2 1.0664 0.86124 0.99576 1.0508 1.04331 
4 1.1322 0.84528 1.04138 0.96472 1.24533 
6 1.0881 0.93121 0.97921 0.90536 1.22904 
8 1.0955 0.89563 1.0132 0.96115 1.25332 
10 1.1177 0.8262 0.96891 1.03763 1.24081 
12 1.09073 0.87213 0.9888 1.00941 1.2462 
14 1.11172 0.84813 0.99233 0.9428 1.15464 
Average Change 1.0878 0.8850 0.9974 0.9840 1.1766 
Volume of 55% 
POPC 15% 
PI(4,5)P2 
30% POPS Added 
Donor 
Alone 
T1 T2 T3 T4 
0 1 1 1 1 1 
2 1.0294 0.8941 1.0237 1.0437 0.9469 
4 1.0925 0.9079 1.0706 0.9517 1.0447 
6 1.1194 0.9723 1.0067 0.9718 1.0635 
8 1.1110 0.9723 1.0548 0.9977 1.0790 
10 1.1844 0.9054 1.0170 1.0702 1.0370 
12 1.1478 0.9924 1.0432 1.0449 1.0398 
14 1.1936 0.9703 1.0517 1.0207 1.0119 
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 Table 9: Change in Donor Emission Fluorescence Intensity Upon Calcium Chloride Addition, 85% POPC 15% PI(4,5)P2, 4 to 1 
Acceptor to Donor 
 
 
 
 
 Table 10: Change in Donor Emission Fluorescence Intensity Divided by Donor Alone Titration, 85% POPC 15% PI(4,5)P2, 4 to 1 
Acceptor to Donor 
 
   
Average Change 1.1100 0.9518 1.1013 1.0126 1.0279 
Volume  
10mM CaCl2  
Added 
Donor Alone T1 T2      T3 
0                     1    1    1 1 
2 1.00564 0.97653 0.97358 1.10244 
4 0.96807 1.01865 1.05727 1.11293 
6 1.00449 0.92757 1.05413 1.1179 
8 0.8802 0.76414 1.03399 1.05542 
10 0.9204 0.8927 0.99204 1.04982 
12 0.93021 0.95459 1.05874 1.11103 
14 0.91071 0.92459 1.04037 0.98219 
Average Change 
in Fluorescence 
Intensity 
               0.952465 0.93235 1.02627 1.06647 
Volume  
10mM CaCl2  
Added 
T1 T2      T3 
0 1.0612 0.9732 1.05736 
2 1.0305 0.9422 1.15914 
4 1.1166 1.0629 1.21558 
6 0.9799 1.0213 1.17674 
8 0.9215 1.1435 1.26812 
10 1.0287 1.0484 1.20534 
12 1.0890 1.1077 1.2629 
14 1.0774 1.1118 1.1404 
Average Change in 
Fluorescence Intensity 
1.0381 1.0514 1.1857 
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Table 11: Change in Donor Emission Fluorescence Intensity Upon 85% POPC 15% PI(4,5)P2 Addition, 4 to 1 Acceptor to Donor 
Volume of 
85% POPC 
15% PI(4,5)P2 
Added 
Donor 
Alone 
T1 T2 T3 
0 1 1 1 1 
3 0.9143 0.9351 0.8741 0.9064 
6 0.8033 0.7703 0.8473 0.8793 
9 0.8281 0.7939 0.7931 0.7724 
12 0.7894 0.7677 0.7239 0.7755 
15 0.7535 0.6322 0.7214 0.7567 
18 0.6510 0.6562 0.6505 0.7411 
Average 
Change 
0.8199 0.7936 0.805 0.8331 
 
 
 
 
 
 
 
Table 12: Change in Fluorescence Intensity Donor Emission Divided by Donor Alone Fluorescence Intensity, 85% POPC 15% 
PI(4,5)P2, 4 to 1 Acceptor to Donor 
Volume of 
85% POPC 
15% PI(4,5)P2 
Added 
T1 T2 T3 
0 0.9046 1.0974 1.0974 
3 0.9252 1.0491 1.0879 
6 0.8675 1.1576 1.2013 
9 0.8672 1.0510 1.0235 
12 0.8799 1.0063 1.0781 
15 0.7590 1.0507 1.1021 
18 0.9119 1.0966 1.2494 
Average 
Change 
0.8736 1.0727 1.1200 
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Table 13: Change in Fluorescence Intensity Upon 70% POPC 30% POPS Addition, 2 to 1 Acceptor to Donor 
Volume of 
70% POPC 
30% POPS 
Added 
T1 
Donor 
Emission 
T1 
Acceptor 
Emission 
T2 
Donor 
Emission 
T2 
Acceptor 
Emission 
Donor 
Alone  
T1 
Donor 
Alone 
T2 
0 1 1 1 1 1 1 
2 0.97825 0.9793 - - 0.96102 - 
3 - - 1.0326 0.8854 - 0.91594 
4 0.9660 0.9911 - - 0.88894 0.91498 
6 0.9566 1.0089 1.0107 0.8904 0.95359 0.87125 
8 0.9721 1.0237 0.9997 0.9121 0.86249 0.83609 
10 0.9389 1.0109 0.9612 0.9038 0.91815 0.89732 
12 .8090 0.9556 0.9909 0.9013 0.91571 0.8855 
14 0.7791 0.9457 0.9376 0.8837 - - 
Average 
Change 
0.9245 0.9894 0.9904 0.9110 0.9286 0.9030 
 
Table 14: Change in Donor Emission Fluorescence Intensity Upon 100% POPC Addition, Donor Alone 
Volume of 100% POPC 
Added (uL) 
T1 T2 T3 
0 1 1 1 
3 0.9484 0.9477 0.9273 
6 0.9619 0.9624 0.9549 
9 0.9518 0.9683 0.8788 
12 0.9023 0.8925 0.8824 
15 0.8520 0.8603 0.8845 
Average Change 0.9361 0.9385 0.9213 
 
 
Table 15: Change in Donor Emission Fluorescence Intensity Upon 100% POPC Addition, 2 to 1 Acceptor to Donor 
 
  
Volume of 100% POPC 
Added (uL) 
T1 T2 T3 
0 1 1 1 
3 0.91346 0.9091 1.0524 
6 0.8465 0.9175 1.0989 
9 0.9411 0.9007 1.0854 
12 0.9031 0.9456 1.0662 
15 0.8811 0.9011 1.0461 
Average Change 0.9142 0.9290 1.0582 
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Table 16: Change in Acceptor Emission Fluorescence Intensity Upon 100% POPC Addition, 2 to 1 Acceptor to Donor 
Volume of 100% POPC 
Added (uL) 
T1 T2 T3 
0 1 1 1 
3 0.9532 0.9561 1.0524 
6 0.9041 0.9822 1.0916 
9 1.0189 0.9717 1.0911 
12 0.9990 1.0664 1.0779 
15 0.9550 1.0158 1.0847 
Average Change 0.9717 0.9987 1.0663 
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8.7 Appendix G: Tables of Changes in Lipid, ANXA2 & CaCl2 During FRET Experiments  
Table 17: 95% POPC 5% PI(4,5)P2, Donor Alone Lipid Titration. Calcium, Protein, and Lipid Concentrations and Ratios throughout 
the Experiment. 
 
Table 18: 95% POPC 5% PI(4,5)P2 Lipid Titration, 3 to 1 Acceptor to Donor. Calcium, Protein, and Lipid Concentrations and Ratios 
throughout the Experiment. 
 
 
Table 19: 95% POPC 5% PI(4,5)P2 Lipid Titration, 4 to 1 Acceptor to Donor. Calcium, Protein, and Lipid Concentrations and Ratios 
throughout the Experiment. 
 
 
Volume 
of 95% 
POPC 5% 
PI(4,5)P2 
Added 
(uL)
Lipid 
Volume 
in L
Lipid 
Concentr
ation (M)
mM Lipid 
Concentr
ation
uM Lipid 
Concentr
ation 
Dilution 
Correcte
d 
Starting 
ANXA2 
Acceptor 
Concentr
ation 
(uM)
Starting 
ANXA2 
Donor 
Concentr
ation 
(uM)
Starting 
ANXA2 
Donor 
(umoles)
Lipid to 
Protein 
Ratio
Starting 
CaCl2 
Concentr
ation 
(mM)
Starting 
CaCl2 
Conc 
mmol
Starting 
CaCl2 
Conc uM
CaCl2 
umol
0 0 0 0 0 0 0.5 30 0 0.5 0.00003 500 30000
3 0.000003 0.000015 0.015 14.28571 0 0.47619 30 30 0.47619 30 476.1905 30000
6 0.000006 0.00003 0.03 27.27273 0 0.454545 30 60 0.454545 30 454.5455 30000
9 0.000009 0.000045 0.045 39.13043 0 0.434783 30 90 0.434783 30 434.7826 30000
12 0.000012 0.00006 0.06 50 0 0.416667 30 120 0.416667 30 416.6667 30000
15 0.000015 0.000075 0.075 60 0 0.4 30 150 0.4 30 400 30000
18 0.000018 0.00009 0.09 69.23077 0 0.384615 30 180 0.384615 30 384.6154 30000
Volume 
of 95% 
POPC 5% 
PI(4,5)P2 
Added 
(uL)
Lipid 
Volume 
in L
Lipid 
Concentr
ation (M)
mM Lipid 
Concentr
ation
uM Lipid 
Concentr
ation 
Dilution 
Correcte
d 
Starting 
ANXA2 
Acceptor 
Concentr
ation 
(uM)
Starting 
ANXA2 
Donor 
Concentr
ation 
(uM)
Starting 
ANXA2 
Donor 
(umoles)
Lipid to 
Protein 
Ratio
Starting 
CaCl2 
Concentr
ation 
(mM)
Starting 
CaCl2 
Conc 
mmol
Starting 
CaCl2 
Conc uM
CaCl2 
umol
0 0 0 0 0 1.5 0.5 30 0 0.5 0.00003 500 30000
3 0.000003 0.000015 0.015 14.28571 1.428571 0.47619 30 7.5 0.47619 30 476.1905 30000
6 0.000006 0.00003 0.03 27.27273 1.363636 0.454545 30 15 0.454545 30 454.5455 30000
9 0.000009 0.000045 0.045 39.13043 1.304348 0.434783 30 22.5 0.434783 30 434.7826 30000
12 0.000012 0.00006 0.06 50 1.25 0.416667 30 30 0.416667 30 416.6667 30000
15 0.000015 0.000075 0.075 60 1.2 0.4 30 37.5 0.4 30 400 30000
18 0.000018 0.00009 0.09 69.23077 1.153846 0.384615 30 45 0.384615 30 384.6154 30000
Volume 
of 95% 
POPC 5% 
PI(4,5)P2 
Added 
(uL)
Lipid 
Volume 
in L
Lipid 
Concentr
ation (M)
mM Lipid 
Concentr
ation
uM Lipid 
Concentr
ation 
Dilution 
Correcte
d 
Starting 
ANXA2 
Acceptor 
Concentr
ation 
(uM)
Starting 
ANXA2 
Donor 
Concentr
ation 
(uM)
Starting 
ANXA2 
Donor 
(umoles)
Lipid to 
Protein 
Ratio
Starting 
CaCl2 
Concentr
ation 
(mM)
Starting 
CaCl2 
Conc 
mmol
Starting 
CaCl2 
Conc uM
CaCl2 
umol
0 0 0 0 0 1 0.25 15 0 0.5 0.00003 500 30000
3 0.000003 0.000015 0.015 14.28571 0.952381 0.238095 15 12 0.47619 30 476.1905 30000
6 0.000006 0.00003 0.03 27.27273 0.909091 0.227273 15 24 0.454545 30 454.5455 30000
9 0.000009 0.000045 0.045 39.13043 0.869565 0.217391 15 36 0.434783 30 434.7826 30000
12 0.000012 0.00006 0.06 50 0.833333 0.208333 15 48 0.416667 30 416.6667 30000
15 0.000015 0.000075 0.075 60 0.8 0.2 15 60 0.4 30 400 30000
14 0.000014 0.00007 0.07 56.75676 0.810811 0.202703 15 56 0.405405 30 405.4054 30000
14 0.000014 0.00007 0.07 56.75676 0.810811 0.202703 15 56 0.405405 30 405.4054 30000
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Table 20: 65% POPC 5% PI(4,5)P2 30% POPS Lipid Titration, 4 to 1 Acceptor to Donor. Calcium, Protein, and Lipid Concentrations 
and Ratios throughout the Experiment. 
 
Table 21: 65% POPC 5% PI(4,5)P2 30% POPS Lipid Titration, Donor Alone. Calcium, Protein, and Lipid Concentrations and Ratios 
throughout the Experiment. 
 
 
Table 22: 55% POPC 15% PI(4,5)P2 30% POPS 4 to 1 Acceptor to Donor CaCl2 Titration. Calcium, EGTA, Protein, and Lipid 
Concentrations and Ratios throughout the Experiment 
 
 
Volume 
of 65% 
POPC 5% 
PI(4,5)P2 
30% 
POPS 
Added 
(uL)
Lipid 
Volume 
in L
Lipid 
Concentr
ation (M)
mM Lipid 
Concentr
ation
uM Lipid 
Concentr
ation 
Dilution 
Correcte
d 
Starting 
ANXA2 
Acceptor 
Concentr
ation 
(uM)
Starting 
ANXA2 
Donor 
Concentr
ation 
(uM)
Starting 
ANXA2 
Donor 
(umoles)
Lipid to 
Protein 
Ratio
Starting 
CaCl2 
Concentr
ation 
(mM)
Starting 
CaCl2 
Conc 
mmol
Starting 
CaCl2 
Conc uM
CaCl2 
umol
0 0 0 0 0 2 0.5 30 0 0.5 0.00003 500 30000
3 0.000003 0.000015 0.015 14.28571 1.904762 0.47619 30 6 0.47619 30 476.1905 30000
6 0.000006 0.00003 0.03 27.27273 1.818182 0.454545 30 12 0.454545 30 454.5455 30000
9 0.000009 0.000045 0.045 39.13043 1.73913 0.434783 30 18 0.434783 30 434.7826 30000
12 0.000012 0.00006 0.06 50 1.666667 0.416667 30 24 0.416667 30 416.6667 30000
15 0.000015 0.000075 0.075 60 1.6 0.4 30 30 0.4 30 400 30000
Volume 
of 65% 
POPC 5% 
PI(4,5)P2 
30% 
POPS 
Added 
(uL)
Lipid 
Volume 
in L
Lipid 
Concentr
ation (M)
mM Lipid 
Concentr
ation
uM Lipid 
Concentr
ation 
Dilution 
Correcte
d 
Starting 
ANXA2 
Acceptor 
Concentr
ation 
(uM)
Starting 
ANXA2 
Donor 
Concentr
ation 
(uM)
Starting 
ANXA2 
Donor 
(umoles)
Lipid to 
Protein 
Ratio
Starting 
CaCl2 
Concentr
ation 
(mM)
Starting 
CaCl2 
Conc 
mmol
Starting 
CaCl2 
Conc uM
CaCl2 
umol
0 0 0 0 0 0 0.5 30 0 0.5 0.00003 500 30000
3 0.000003 0.000015 0.015 14.28571 0 0.47619 30 30 0.47619 30 476.1905 30000
6 0.000006 0.00003 0.03 27.27273 0 0.454545 30 60 0.454545 30 454.5455 30000
9 0.000009 0.000045 0.045 39.13043 0 0.434783 30 90 0.434783 30 434.7826 30000
12 0.000012 0.00006 0.06 50 0 0.416667 30 120 0.416667 30 416.6667 30000
15 0.000015 0.000075 0.075 60 0 0.4 30 150 0.4 30 400 30000
Volume 
10mM 
CaCl2 
Added 
(uL)
CaCl2 
Volume 
in L
CaCl2 
Concentr
ation (M)
mM 
CaCl2 
Concentr
ation
Dilution 
Correcte
d uM 
CaCl2 
Concentr
ation
Starting 
ANXA2 
Acceptor 
Concentr
ation 
(uM)
Starting 
ANXA2 
Donor 
Concentr
ation 
(uM)
Starting 
ANXA2 
Donor 
Not 
Dilution 
Correcte
d 
(umoles)
Ratio 
Lipid to 
Protein
Starting 
EGTA 
Concentr
ation 
(mM)
Starting 
EGTA 
conc uM
EGTA-
CaCl2
Starting 
EGTA Not 
Dilution 
Correcte
d
uM 55% 
POPC 
15% 
PI(4,5)P2 
30% 
POPS 
Lipid 
Concentr
ation
0 0 0 0 0 2 0.5 30 30 0.5 500 500 30000 75
2 0.000002 0.000333 0.333333 322.5806 1.935484 0.483871 30 30 0.483871 483.871 161.2903 30000 72.58065
4 0.000004 0.000667 0.666667 625 1.875 0.46875 30 29.03226 0.46875 468.75 -156.25 30000 68.04435
6 0.000006 0.001 1 909.0909 1.818182 0.454545 30 27.21774 0.454545 454.5455 -454.545 30000 61.8585
8 0.000008 0.001333 1.333333 1176.471 1.764706 0.441176 30 24.7434 0.441176 441.1765 -735.294 30000 54.58103
10 0.00001 0.001667 1.666667 1428.571 1.714286 0.428571 30 21.83241 0.428571 428.5714 -1000 30000 46.78374
12 0.000012 0.002 2 1666.667 1.666667 0.416667 30 18.7135 0.416667 416.6667 -1250 30000 38.98645
14 0.000014 0.002333 2.333333 1891.892 1.621622 0.405405 30 15.59458 0.405405 405.4054 -1486.49 30000 31.61064
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Table 23: 55% POPC 15% PI(4,5)P2 30% POPS Donor Alone CaCl2 Titration. Calcium, EGTA, Protein, and Lipid Concentrations and 
Ratios throughout the Experiment. 
 
 
 
 
 
Volume 
10mM 
CaCl2 
Added 
(uL)
CaCl2 
Volume 
in L
CaCl2 
Concentr
ation (M)
mM 
CaCl2 
Concentr
ation
Dilution 
Correcte
d uM 
CaCl2 
Concentr
ation
Starting 
ANXA2 
Acceptor 
Concentr
ation 
(uM)
Starting 
ANXA2 
Donor 
Concentr
ation 
(uM)
Starting 
ANXA2 
Donor 
Not 
Dilution 
Correcte
d 
(umoles)
Ratio 
Lipid to 
Protein
Starting 
EGTA 
Concentr
ation 
(mM)
Starting 
EGTA 
conc uM
EGTA-
CaCl2
Starting 
EGTA Not 
Dilution 
Correcte
d
uM 55% 
POPC 
15% 
PI(4,5)P2 
30% 
POPS 
Lipid 
Concentr
ation
0 0 0 0 0 0 0.5 30 150 0.5 500 500 30000 75
2 0.000002 0.000333 0.333333 322.5806 0 0.483871 30 150 0.483871 483.871 161.2903 30000 72.58065
4 0.000004 0.000667 0.666667 625 0 0.46875 30 145.1613 0.46875 468.75 -156.25 30000 68.04435
6 0.000006 0.001 1 909.0909 0 0.454545 30 136.0887 0.454545 454.5455 -454.545 30000 61.8585
8 0.000008 0.001333 1.333333 1176.471 0 0.441176 30 123.717 0.441176 441.1765 -735.294 30000 54.58103
10 0.00001 0.001667 1.666667 1428.571 0 0.428571 30 109.1621 0.428571 428.5714 -1000 30000 46.78374
12 0.000012 0.002 2 1666.667 0 0.416667 30 93.56749 0.416667 416.6667 -1250 30000 38.98645
14 0.000014 0.002333 2.333333 1891.892 0 0.405405 30 77.9729 0.405405 405.4054 -1486.49 30000 31.61064
Volume 
10mM 
CaCl2 
Added 
(uL)
CaCl2 
Volume 
in L
CaCl2 
Concentr
ation (M)
mM 
CaCl2 
Concentr
ation
Dilution 
Correcte
d uM 
CaCl2 
Concentr
ation
Starting 
ANXA2 
Acceptor 
Concentr
ation 
(uM)
Starting 
ANXA2 
Donor 
Concentr
ation 
(uM)
Starting 
ANXA2 
Donor 
Not 
Dilution 
Correcte
d 
(umoles)
Ratio 
Lipid to 
Protein
Starting 
EGTA 
Concentr
ation 
(mM)
Starting 
EGTA 
conc uM
EGTA-
CaCl2
Starting 
EGTA Not 
Dilution 
Correcte
d
uM 85% 
POPC 
15% 
PI(4,5)P2 
Lipid 
Concentr
ation
0 0 0 0 0 2 0.5 30 30 0.5 500 500 30000 75
2 0.000002 0.000333 0.333333 322.5806 1.935484 0.483871 30 30 0.483871 483.871 161.2903 30000 72.58065
4 0.000004 0.000667 0.666667 625 1.875 0.46875 30 29.03226 0.46875 468.75 -156.25 30000 68.04435
6 0.000006 0.001 1 909.0909 1.818182 0.454545 30 27.21774 0.454545 454.5455 -454.545 30000 61.8585
8 0.000008 0.001333 1.333333 1176.471 1.764706 0.441176 30 24.7434 0.441176 441.1765 -735.294 30000 54.58103
10 0.00001 0.001667 1.666667 1428.571 1.714286 0.428571 30 21.83241 0.428571 428.5714 -1000 30000 46.78374
12 0.000012 0.002 2 1666.667 1.666667 0.416667 30 18.7135 0.416667 416.6667 -1250 30000 38.98645
14 0.000014 0.002333 2.333333 1891.892 1.621622 0.405405 30 15.59458 0.405405 405.4054 -1486.49 30000 31.61064
Table 24: 85% POPC 15% PI(4,5)P2, 4 to 1 Acceptor to Donor CaCl2 Titration. Calcium, EGTA, Protein, and Lipid Concentrations and Ratios 
throughout the Experiment. 
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Table 25: 85% POPC 15% PI(4,5)P2, Donor Alone CaCl2 Titration. Calcium, EGTA, Protein, and Lipid Concentrations and Ratios 
throughout the Experiment. 
 
Table 26: 85% POPC 15% PI(4,5)P2 Lipid Titration, Donor Alone. Calcium, Protein, and Lipid Concentrations and Ratios 
throughout the Experiment. 
 
 
Table 27: 85% POPC 15% PI(4,5)P2 Lipid Titration, 4 to 1 Acceptor to Donor. Calcium, Protein, and Lipid Concentrations and 
Ratios throughout the Experiment. 
 
 
Volume 
10mM 
CaCl2 
Added 
(uL)
CaCl2 
Volume 
in L
CaCl2 
Concentr
ation (M)
mM 
CaCl2 
Concentr
ation
Dilution 
Correcte
d uM 
CaCl2 
Concentr
ation
Starting 
ANXA2 
Acceptor 
Concentr
ation 
(uM)
Starting 
ANXA2 
Donor 
Concentr
ation 
(uM)
Starting 
ANXA2 
Donor 
Not 
Dilution 
Correcte
d 
(umoles)
Ratio 
Lipid to 
Protein
Starting 
EGTA 
Concentr
ation 
(mM)
Starting 
EGTA 
conc uM
EGTA-
CaCl2
Starting 
EGTA Not 
Dilution 
Correcte
d
uM 85% 
POPC 
15% 
PI(4,5)P2 
Lipid 
Concentr
ation
0 0 0 0 0 0 0.5 30 150 0.5 500 500 30000 75
2 0.000002 0.000333 0.333333 322.5806 0 0.483871 30 150 0.483871 483.871 161.2903 30000 72.58065
4 0.000004 0.000667 0.666667 625 0 0.46875 30 145.1613 0.46875 468.75 -156.25 30000 68.04435
6 0.000006 0.001 1 909.0909 0 0.454545 30 136.0887 0.454545 454.5455 -454.545 30000 61.8585
8 0.000008 0.001333 1.333333 1176.471 0 0.441176 30 123.717 0.441176 441.1765 -735.294 30000 54.58103
10 0.00001 0.001667 1.666667 1428.571 0 0.428571 30 109.1621 0.428571 428.5714 -1000 30000 46.78374
12 0.000012 0.002 2 1666.667 0 0.416667 30 93.56749 0.416667 416.6667 -1250 30000 38.98645
14 0.000014 0.002333 2.333333 1891.892 0 0.405405 30 77.9729 0.405405 405.4054 -1486.49 30000 31.61064
Volume 
of 85% 
POPC 
15% 
PI(4,5)P2 
Added 
(uL)
Lipid 
Volume 
in L
Lipid 
Concentr
ation (M)
mM Lipid 
Concentr
ation
uM Lipid 
Concentr
ation 
Dilution 
Correcte
d 
Starting 
ANXA2 
Acceptor 
Concentr
ation 
(uM)
Starting 
ANXA2 
Donor 
Concentr
ation 
(uM)
Starting 
ANXA2 
Donor 
(umoles)
Lipid to 
Protein 
Ratio
Starting 
CaCl2 
Concentr
ation 
(mM)
Starting 
CaCl2 
Conc 
mmol
Starting 
CaCl2 
Conc uM
CaCl2 
umol
0 0 0 0 0 0 0.5 30 0 0.5 0.00003 500 30000
3 0.000003 0.000015 0.015 14.28571 0 0.47619 30 30 0.47619 30 476.1905 30000
6 0.000006 0.00003 0.03 27.27273 0 0.454545 30 60 0.454545 30 454.5455 30000
9 0.000009 0.000045 0.045 39.13043 0 0.434783 30 90 0.434783 30 434.7826 30000
12 0.000012 0.00006 0.06 50 0 0.416667 30 120 0.416667 30 416.6667 30000
15 0.000015 0.000075 0.075 60 0 0.4 30 150 0.4 30 400 30000
18 0.000018 0.00009 0.09 69.23077 0 0.384615 30 180 0.384615 30 384.6154 30000
Volume 
of 85% 
POPC 
15% 
PI(4,5)P2 
Added 
(uL)
Lipid 
Volume 
in L
Lipid 
Concentr
ation (M)
mM Lipid 
Concentr
ation
uM Lipid 
Concentr
ation 
Dilution 
Correcte
d 
Starting 
ANXA2 
Acceptor 
Concentr
ation 
(uM)
Starting 
ANXA2 
Donor 
Concentr
ation 
(uM)
Starting 
ANXA2 
Donor 
(umoles)
Lipid to 
Protein 
Ratio
Starting 
CaCl2 
Concentr
ation 
(mM)
Starting 
CaCl2 
Conc 
mmol
Starting 
CaCl2 
Conc uM
CaCl2 
umol
0 0 0 0 0 2 0.5 30 0 0.5 0.00003 500 30000
3 0.000003 0.000015 0.015 14.28571 1.904762 0.47619 30 6 0.47619 30 476.1905 30000
6 0.000006 0.00003 0.03 27.27273 1.818182 0.454545 30 12 0.454545 30 454.5455 30000
9 0.000009 0.000045 0.045 39.13043 1.73913 0.434783 30 18 0.434783 30 434.7826 30000
12 0.000012 0.00006 0.06 50 1.666667 0.416667 30 24 0.416667 30 416.6667 30000
15 0.000015 0.000075 0.075 60 1.6 0.4 30 30 0.4 30 400 30000
18 0.000018 0.00009 0.09 69.23077 1.538462 0.384615 30 36 0.384615 30 384.6154 30000
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Table 28: 70% POPC 30% POPS Lipid Titration, Donor Alone T1. Calcium, Protein, and Lipid Concentrations and Ratios 
throughout the Experiment. 
 
  
Table 29: 70% POPC 30% POPS Lipid Titration, Donor Alone T2. Calcium, Protein, and Lipid Concentrations and Ratios 
throughout the Experiment. 
 
Table 30: 70% POPC 30% POPS Lipid Titration, 2 to 1 Acceptor to Donor T1. Calcium, Protein, and Lipid Concentrations and 
Ratios throughout the Experiment. 
 
 
Volume 
of 70% 
POPC 
30% 
POPS 
Added 
(uL)
Lipid 
Volume 
in L
Lipid 
Concentr
ation (M)
mM Lipid 
Concentr
ation
uM Lipid 
Concentr
ation 
Dilution 
Correcte
d 
Starting 
ANXA2 
Acceptor 
Concentr
ation 
(uM)
Starting 
ANXA2 
Donor 
Concentr
ation 
(uM)
Starting 
ANXA2 
Donor 
(umoles)
Lipid to 
Protein 
Ratio
Starting 
CaCl2 
Concentr
ation 
(mM)
Starting 
CaCl2 
Conc 
mmol
Starting 
CaCl2 
Conc uM
CaCl2 
umol
0 0 0 0 0 0 0.5 30 0 0.5 0.00003 500 30000
2 0.000002 0.00001 0.01 9.677419 0 0.483871 30 20 0.483871 30 483.871 30000
4 0.000004 0.00002 0.02 18.75 0 0.46875 30 40 0.46875 30 468.75 30000
6 0.000006 0.00003 0.03 27.27273 0 0.454545 30 60 0.454545 30 454.5455 30000
8 0.000008 0.00004 0.04 35.29412 0 0.441176 30 80 0.441176 30 441.1765 30000
10 0.00001 0.00005 0.05 42.85714 0 0.428571 30 100 0.428571 30 428.5714 30000
12 0.000012 0.00006 0.06 50 0 0.416667 30 120 0.416667 30 416.6667 30000
Volume 
of 70% 
POPC 
30% 
POPS 
Added 
(uL)
Lipid 
Volume 
in L
Lipid 
Concentr
ation (M)
mM Lipid 
Concentr
ation
uM Lipid 
Concentr
ation 
Dilution 
Correcte
d 
Starting 
ANXA2 
Acceptor 
Concentr
ation 
(uM)
Starting 
ANXA2 
Donor 
Concentr
ation 
(uM)
Starting 
ANXA2 
Donor 
(umoles)
Lipid to 
Protein 
Ratio
Starting 
CaCl2 
Concentr
ation 
(mM)
Starting 
CaCl2 
Conc 
mmol
Starting 
CaCl2 
Conc uM
CaCl2 
umol
0 0 0 0 0 0 0.5 30 0 0.5 0.00003 500 30000
3 0.000003 0.000015 0.015 14.28571 0 0.47619 30 30 0.47619 30 476.1905 30000
4 0.000004 0.00002 0.02 18.75 0 0.46875 30 40 0.46875 30 468.75 30000
6 0.000006 0.00003 0.03 27.27273 0 0.454545 30 60 0.454545 30 454.5455 30000
8 0.000008 0.00004 0.04 35.29412 0 0.441176 30 80 0.441176 30 441.1765 30000
10 0.00001 0.00005 0.05 42.85714 0 0.428571 30 100 0.428571 30 428.5714 30000
12 0.000012 0.00006 0.06 50 0 0.416667 30 120 0.416667 30 416.6667 30000
Volume 
of 70% 
POPC 
30% 
POPS 
Added 
(uL)
Lipid 
Volume 
in L
Lipid 
Concentr
ation (M)
mM Lipid 
Concentr
ation
uM Lipid 
Concentr
ation 
Dilution 
Correcte
d 
Starting 
ANXA2 
Acceptor 
Concentr
ation 
(uM)
Starting 
ANXA2 
Donor 
Concentr
ation 
(uM)
Starting 
ANXA2 
Donor 
(umoles)
Lipid to 
Protein 
Ratio
Starting 
CaCl2 
Concentr
ation 
(mM)
Starting 
CaCl2 
Conc 
mmol
Starting 
CaCl2 
Conc uM
CaCl2 
umol
0 0 0 0 0 1 0.5 30 0 0.5 0.00003 500 30000
2 0.000002 0.00001 0.01 9.677419 0.967742 0.483871 30 6.666667 0.483871 30 483.871 30000
4 0.000004 0.00002 0.02 18.75 0.9375 0.46875 30 13.33333 0.46875 30 468.75 30000
6 0.000006 0.00003 0.03 27.27273 0.909091 0.454545 30 20 0.454545 30 454.5455 30000
8 0.000008 0.00004 0.04 35.29412 0.882353 0.441176 30 26.66667 0.441176 30 441.1765 30000
10 0.00001 0.00005 0.05 42.85714 0.857143 0.428571 30 33.33333 0.428571 30 428.5714 30000
12 0.000012 0.00006 0.06 50 0.833333 0.416667 30 40 0.416667 30 416.6667 30000
14 0.000014 0.00007 0.07 56.75676 0.810811 0.405405 30 46.66667 0.405405 30 405.4054 30000
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Table 31: 70% POPC 30% POPS Lipid Titration, 2 to 1 Acceptor to Donor T2. Calcium, Protein, and Lipid Concentrations and 
Ratios throughout the Experiment. 
 
Table 32: 100% POPC 30% Lipid Titration, Donor Alone. Calcium, Protein, and Lipid Concentrations and Ratios throughout the 
Experiment. 
 
Table 33: 100% POPC 30% Lipid Titration, 2 to 1 Acceptor to Donor. Calcium, Protein, and Lipid Concentrations and Ratios 
throughout the Experiment. 
 
 
Volume 
of 70% 
POPC 
30% 
POPS 
Added 
(uL)
Lipid 
Volume 
in L
Lipid 
Concentr
ation (M)
mM Lipid 
Concentr
ation
uM Lipid 
Concentr
ation 
Dilution 
Correcte
d 
Starting 
ANXA2 
Acceptor 
Concentr
ation 
(uM)
Starting 
ANXA2 
Donor 
Concentr
ation 
(uM)
Starting 
ANXA2 
Donor 
(umoles)
Lipid to 
Protein 
Ratio
Starting 
CaCl2 
Concentr
ation 
(mM)
Starting 
CaCl2 
Conc 
mmol
Starting 
CaCl2 
Conc uM
CaCl2 
umol
0 0 0 0 0 1 0.5 30 0 0.5 0.00003 500 30000
3 0.000003 0.000015 0.015 14.28571 0.952381 0.47619 30 10 0.47619 30 476.1905 30000
6 0.000006 0.00003 0.03 27.27273 0.909091 0.454545 30 20 0.454545 30 454.5455 30000
8 0.000008 0.00004 0.04 35.29412 0.882353 0.441176 30 26.66667 0.441176 30 441.1765 30000
10 0.00001 0.00005 0.05 42.85714 0.857143 0.428571 30 33.33333 0.428571 30 428.5714 30000
12 0.000012 0.00006 0.06 50 0.833333 0.416667 30 40 0.416667 30 416.6667 30000
14 0.000014 0.00007 0.07 56.75676 0.810811 0.405405 30 46.66667 0.405405 30 405.4054 30000
Volume 
of 100% 
POPC 
Added 
(uL)
Lipid 
Volume 
in L
Lipid 
Concentr
ation (M)
mM Lipid 
Concentr
ation
uM Lipid 
Concentr
ation 
Dilution 
Correcte
d 
Starting 
ANXA2 
Acceptor 
Concentr
ation 
(uM)
Starting 
ANXA2 
Donor 
Concentr
ation 
(uM)
Starting 
ANXA2 
Donor 
(umoles)
Lipid to 
Protein 
Ratio
Starting 
CaCl2 
Concentr
ation 
(mM)
Starting 
CaCl2 
Conc 
mmol
Starting 
CaCl2 
Conc uM
CaCl2 
umol
0 0 0 0 0 0 0.5 30 0 0.5 0.00003 500 30000
3 0.000003 0.000015 0.015 14.28571 0 0.47619 30 30 0.47619 30 476.1905 30000
6 0.000006 0.00003 0.03 27.27273 0 0.454545 30 60 0.454545 30 454.5455 30000
9 0.000009 0.000045 0.045 39.13043 0 0.434783 30 90 0.434783 30 434.7826 30000
12 0.000012 0.00006 0.06 50 0 0.416667 30 120 0.416667 30 416.6667 30000
15 0.000015 0.000075 0.075 60 0 0.4 30 150 0.4 30 400 30000
Volume 
of 100% 
POPC 
Added 
(uL)
Lipid 
Volume 
in L
Lipid 
Concentr
ation (M)
mM Lipid 
Concentr
ation
uM Lipid 
Concentr
ation 
Dilution 
Correcte
d 
Starting 
ANXA2 
Acceptor 
Concentr
ation 
(uM)
Starting 
ANXA2 
Donor 
Concentr
ation 
(uM)
Starting 
ANXA2 
Donor 
(umoles)
Lipid to 
Protein 
Ratio
Starting 
CaCl2 
Concentr
ation 
(mM)
Starting 
CaCl2 
Conc 
mmol
Starting 
CaCl2 
Conc uM
CaCl2 
umol
0 0 0 0 0 1 0.5 30 0 0.5 0.00003 500 30000
3 0.000003 0.000015 0.015 14.28571 0.952381 0.47619 30 10 0.47619 30 476.1905 30000
6 0.000006 0.00003 0.03 27.27273 0.909091 0.454545 30 20 0.454545 30 454.5455 30000
9 0.000009 0.000045 0.045 39.13043 0.869565 0.434783 30 30 0.434783 30 434.7826 30000
12 0.000012 0.00006 0.06 50 0.833333 0.416667 30 40 0.416667 30 416.6667 30000
15 0.000015 0.000075 0.075 60 0.8 0.4 30 50 0.4 30 400 30000
